---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence. Covers Launch-HTN, Advance-HTN, Transform-HTN, Target-HTN, Explore-CKD, Explore-OSA, and 1 further heading. 467 evidence topics quoted from 59 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 Launch-HTN

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.1-2"></a>

###### Main objective in the EU Clinical Trials Information System record

> “To assess the effect of Lorundrostat when added to prescribed AHT on SBP in subjects with hypertension”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.1-3"></a>

###### Objective stated in the publication

> “To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension.”
> “The phase 3 Launch-HTN randomized clinical trial evaluated the efficacy, tolerability, and safety of lorundrostat in participants with uncontrolled hypertension, including those with apparent treatment-resistant hypertension.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-11-22”
> “Primary Completion (Actual) 2024-12-10”
> “Study Completion (Actual) 2025-01-24”
> “First Posted 2023-12-01”
> “Last Update Posted 2026-05-01”
> “No longer looking for participants”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 184 locations”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.2-3"></a>

###### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Alabama Locations”; “Arizona Locations”; “California Locations”; “Connecticut Locations”; “Florida Locations”; “Georgia Locations”; “Idaho Locations”; “Illinois Locations”; “Indiana Locations”; “Kentucky Locations”; “Louisiana Locations”; “Massachusetts Locations”; “Mississippi Locations”; “Missouri Locations”; “Nebraska Locations”; “Nevada Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Oklahoma Locations”; “Pennsylvania Locations”; “Tennessee Locations”; “Texas Locations”; “Utah Locations”; “Virginia Locations” |
| Australia | “Heidelberg Heights, Australia”; “St Albans, Australia”; “Castle Hill, New South Wales, Australia”; “Gosford, New South Wales, Australia”; “Waratah, New South Wales, Australia”; “Sippy Downs, Queensland, Australia”; “Southport, Queensland, Australia”; “Taringa, Queensland, Australia”; “Adelaide, South Australia, Australia”; “Hobart, Tasmania, Australia”; “Perth, Western Australia, Australia” |
| Bulgaria | “Gabrovo, Bulgaria”; “Pleven, Bulgaria”; “Sofia, Bulgaria”; “Stara Zagora, Bulgaria”; “Veliko Tarnovo, Bulgaria” |
| Canada | “Edmonton, Alberta, Canada”; “East York, Ontario, Canada”; “Montreal, Quebec, Canada” |
| France | “Annecy, France”; “Bordeaux, France”; “Nîmes, France”; “Saint-Priest-en-Jarez, France”; “Strasbourg, France” |
| Germany | “Berlin, Germany”; “Deggingen, Germany”; “Karlsruhe, Germany”; “Leipzig, Germany”; “Wiesbaden, Germany”; “Hanover, Lower Saxony, Germany”; “Mainz, Rhineland-Palatinate, Germany”; “Dresden, Saxony, Germany”; “Leipzig, Saxony, Germany” |
| Italy | “Ancona, Italy”; “Bologna, Italy”; “Brescia, Italy”; “Ferrara, Italy”; “Genova, Italy”; “L’Aquila, Italy”; “Messina, Italy”; “Milan, Italy”; “Modena, Italy”; “Naples, Italy”; “Pavia, Italy”; “Pisa, Italy”; “Rome, Italy”; “Rozzano, Milan, Italy”; “Roma, Rome, Italy” |
| Netherlands | “Utrecht, Netherlands”; “Nijmegen, Gelderland, Netherlands”; “Amsterdam, North Holland, Netherlands”; “Dordrecht, South Holland, Netherlands” |
| Poland | “Katowice, Poland”; “Lodz, Poland”; “Olsztyn, Poland”; “Krakow, Lesser Poland Voivodeship, Poland”; “Lubin, Polska, Poland”; “Skierniewice, Polska, Poland”; “Warsaw, Polska, Poland”; “Olsztyn, Warmian-Masurian Voivodeship, Poland” |
| Puerto Rico | “San Juan, Puerto Rico” |
| Romania | “Brasov, Romania”; “Bucharest, Romania”; “Cluj-Napoca, Romania”; “Craiova, Romania”; “Oradea, Romania”; “Timișoara, Romania”; “Târgu Mureş, Mureș County, Romania”; “Timișoara, Timiș County, Romania” |
| Spain | “Badajoz, Spain”; “Barcelona, Spain”; “Córdoba, Spain”; “Granada, Spain”; “Madrid, Spain”; “Santiago de Compostela, Spain”; “Valencia, Spain” |
| United Kingdom | “Aberdeen, United Kingdom”; “Birmingham, United Kingdom”; “Canterbury, United Kingdom”; “Carshalton, United Kingdom”; “Chippenham, United Kingdom”; “Glasgow, United Kingdom”; “Newquay, United Kingdom”; “Sheffield, United Kingdom”; “Stockton-on-Tees, United Kingdom”; “Fowey, Great Britain, United Kingdom”; “London, Great Britain, United Kingdom”; “Plymouth, Great Britain, United Kingdom”; “Torpoint, Great Britain, United Kingdom”; “Canterbury, Kent, United Kingdom” |

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.2-4"></a>

###### Enrollment period, sites, and countries reported in the publication

> “In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025.”
> “The current double-blind, placebo-controlled randomized clinical trial screened participants at 159 sites across 13 countries. The participants were recruited by investigators from primary and secondary care clinics.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.2-5"></a>

###### EU member states, trial start, and end of trial in the EU Clinical Trials Information System record

> “Locations Germany, Romania, Italy, France, Netherlands, Spain, Poland, Bulgaria”
> “Start of trial 17/04/2024”
> “End of trial 09/01/2025”
> “Global end of trial 24/01/2025”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.2-6"></a>

###### Trial and recruitment dates by EU member state

| Member state | Status | Decision date | Trial start date | Trial end | Recruitment start | Recruitment end |
| --- | --- | --- | --- | --- | --- | --- |
| Spain | “Ended” | “08/04/2024” | “23/04/2024” | “03/01/2025” | “29/05/2024” | “18/10/2024” |
| Germany | “Ended” | “10/04/2024” | “18/04/2024” | “09/01/2025” | “28/05/2024” | “18/10/2024” |
| France | “Ended” | “10/04/2024” | “31/05/2024” | “02/01/2025” | “05/09/2024” | “18/10/2024” |
| Italy | “Ended” | “10/04/2024” | “07/05/2024” | “16/01/2025” | “04/06/2024” | “18/10/2024” |
| Netherlands | “Ended” | “11/04/2024” | “22/05/2024” | “06/01/2025” | “26/08/2024” | “18/10/2024” |
| Poland | “Ended” | “12/04/2024” | “08/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Bulgaria | “Ended” | “15/04/2024” | “17/04/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Romania | “Ended” | “15/04/2024” | “27/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.2-7"></a>

###### Presentation and publication dates stated by the company

> “Results from Launch-HTN were presented in a late-breaking session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) on Saturday, May 24, 2025, at 10:00am CEST.”

Source: [Mineralys Therapeutics press release, ESH 2025 Launch-HTN presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/72/mineralys-therapeutics-announces-late-breaking-presentation)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Official title in the ClinicalTrials.gov record

> “A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.3-2"></a>

###### Design details in the ClinicalTrials.gov record

> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Double”
> “Other Study ID Numbers MLS-101-301”
> “Phase Phase 3”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.3-3"></a>

###### Study periods in the ClinicalTrials.gov detailed description

> “The study consists of a 2-week screening period with a 2-week single-blind run-in period followed by a 12-week randomized, double-blind, placebo-controlled, parallel arm period. Following the randomized period subjects will be offered an opportunity to participate in an open-label extension (OLE) study.”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.3-4"></a>

###### Trial phase in the EU Clinical Trials Information System record

> “Trial Phase Therapeutic confirmatory (Phase III)”
> “Medical condition(s) Uncontrolled and Resistant Hypertension”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.3-5"></a>

###### Trial phases, randomization, and stratification in the publication

> “The trial was composed of 3 phases: screening, a 2-week single-blind placebo run-in, and a 12-week randomized, double-blind treatment phase (eFigure 1 in Supplement 1). Upon completion, participants had the option to enroll in an open-label extension trial of lorundrostat or participate in a 2-week safety follow-up. Participants continued taking their prescribed antihypertensive medications for the duration of the trial.”
> “Random permuted block sizes of 4 and 8 were used for randomization, which was stratified by geography (Australia, Canada, Europe, and the US). The randomization sequence was implemented using the Rave RTSM (a randomization and trial supply management system manufactured by Medidata).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.3-6"></a>

###### Blinding and oversight

> “The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6. The treatment assignment was masked to participants, investigators, individuals assessing the outcomes, and individuals analyzing the data until the final database lock.”
> “An independent, unblinded data and safety monitoring committee assessed the study.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.3-7"></a>

###### Blood pressure measurement protocol

> “Unattended, automated office BP was assessed at screening, at randomization (baseline), at weeks 2, 4, 6, 8, and 12 during the double-blind treatment phase, and at an optional safety follow-up visit.”
> “Each site was provided with an identical automated oscillometric BP device (MicroLife WatchBP Office AFIB), training, and an instruction manual for collecting BP measurements. All BP was measured with an appropriately sized cuff on the same arm of the participant throughout the trial at approximately the same time, preferably in the morning. After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.”
> “A standing measurement followed the seated measurements to monitor for orthostatic hypotension.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.3-8"></a>

###### Design described by the company: background medications continued

> “Launch-HTN reflects the real-world setting for clinicians by utilizing automated office blood pressure (AOBP) measurement and allowing participants to stay on their existing medications.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “At least 18 years of age at the time of signing the informed consent form (ICF)”
> “At Screening and Randomization: AOBP SBP of ≥135 and ≤180 mmHg plus AOBP DBP of ≥65 and ≤110 mmHg, or AOBP DBP of ≥90 and ≤110 mmHg”
> “Taking between 2 and 5 AHT medications”
> “History of hypertension lasting at least 6 months prior to Screening”
> “Body mass index (BMI) of ≥18 kg/m2 at Screening”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant, plan to become pregnant, or are breastfeeding”
> “Participation in a study involving any investigational device or small-molecule drug within 4 weeks or 6 months for biologic (antibody) drugs prior to the Screening Visit”
> “eGFR <45 mL/min/1.73m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula”
> “Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization”
> “Serum sodium <135 mmol/L (corrected for hyperglycemia) at Screening.”
> “History of heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months prior to the Screening Visit.”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.4-3"></a>

###### Ages and sexes eligible in the ClinicalTrials.gov record

> “Ages Eligible for Study 18 Years and older”
> “Sexes Eligible for Study All”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.4-4"></a>

###### Age range in the EU Clinical Trials Information System record

> “Age range 65+ years, 18-64 years”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.4-5"></a>

###### Trial population and prohibited medications in the publication

> “Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.”
> “The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening. The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.4-6"></a>

###### Additional inclusion criteria in the supplementary eMethods

> “Taking between 2 and 5 prescribed antihypertensive medications for 1 month prior Screening, include thiazide or thiazide-like diuretic which may be initiated prior/at Run-in and must remain stable until Randomization”
> “Serum cortisol (morning measurement, blood draw as close to 8 a.m. as possible but before 10 a.m.) between 3 and 22 ug/dL, inclusive, at Screening”
> “Arm circumference <52 centimeters at Screening”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.4-7"></a>

###### Additional exclusion criteria in the supplementary eMethods

> “History of clinically significant hyponatremia (sodium <130 mmol/L) or chronic and/or recurrent mild hyponatremia (sodium <135 mmol/L) within 1 year prior to Screening”
> “History of adrenal insufficiency or an abnormal ACTH stimulation test within 1 year prior to Screening”
> “Current, known or presumed white coat hypertension/significant white coat effect (>20 mmHg elevation in clinic BP compared with historical home BP monitoring assessments)”
> “Current, known or presumed orthostatic hypotension”
> “Secondary cause of hypertension with the exception of sleep apnea or primary aldosteronism with subject able to discontinue use of MRA.”
> “Diabetes mellitus with a glycosylated hemoglobin (HbA1C) >9% (>74.9 mmol/mol) at Screening”
> “Treatment with MRAs and/or ENaC inhibitors within 1 month of the Screening Visit”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Intervention |
| --- | --- |
| “Placebo Comparator: Placebo” | “Placebo once daily (QD) for 12 weeks” |
| “Experimental: Dose 1” | “50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks” |
| “Experimental: Dose 2” | “50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria” |

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.5-2"></a>

###### Randomization ratio and criteria for escalation to 100 mg at week 6

> “Upon confirmation of eligibility for randomization after the placebo run-in phase, participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).”
> “The participants in the lorundrostat group who did not meet all of the prespecified criteria at week 6 continued to receive the 50-mg dose for the remaining 6 weeks of double-blind treatment.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.5-3"></a>

###### Administration, dose modification, and adherence reminders

> “Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning. Participants were reminded about taking their trial medication using a smartphone application (AiCure).”
> “The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.5-4"></a>

###### Background antihypertensive therapy

> “Participants continued taking their prescribed antihypertensive medications for the duration of the trial.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Change in Automated Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Registered primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Week 6” |
| Secondary | “Proportion of subjects with AOBP SBP <130 mmHg at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 12 in subjects randomized to lorundrostat 50 mg QD with escalation to lorundrostat 100 mg QD compared to subjects randomized to placebo” | “Week 12” |
| Secondary | “Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 3 or more prescribed AHT medications” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 6 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at week 6 (within-subjects analysis)” | “Week 12” |

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary outcome and key secondary outcomes in the publication

> “The primary efficacy outcome was the change in office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. The key secondary outcomes controlled for multiplicity and included the proportion of participants with an office systolic BP of less than 130 mm Hg at week 6; change in office systolic BP at week 6 in participants taking 2 prescribed antihypertensive medications or taking 3 or more prescribed antihypertensive medications; change in office systolic BP from baseline by continuous body mass index (BMI; calculated as weight in kilograms divided by height in meters squared); change in office systolic BP at week 12; and change in office systolic BP from baseline at week 12 in participants who met prespecified criteria and were escalated from 50 mg to 100 mg of lorundrostat after week 6 (eTable 1 in Supplement 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-3"></a>

###### Primary endpoint at week 6 pooled across both lorundrostat groups

> “Efficacy evaluations at week 6 included participants in both lorundrostat groups because both groups were randomized to receive 50 mg of lorundrostat for the first 6 weeks.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-4"></a>

###### Choice of unattended automated office measurement stated by the investigators

> “Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.”
> “The current trial aimed to minimize the variable nature of office BP measurement by (1) obtaining measurements prior to the intake of morning medications, (2) using unattended BP measurements to limit the white-coat effect, and (3) using the mean of repeated BP measurements to reduce intraindividual variability.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-5"></a>

###### Automated office blood pressure in the American Heart Association scientific statement

> “AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.”
> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”
> “Unattended AOBP has been associated with a lower prevalence of white-coat effect compared with office BP measured through auscultation and reduces the possibility of human error in BP measurement.”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="topic-3.1.1.6.1-6"></a>

###### Difference between unattended and attended automated office measurements

> “The unattended systolic BP and diastolic BP were −2.7 (−4.7 to −0.6) and −0.9 (−1.8 to −0.1) mm Hg lower than attended BPs.”
> “Standardized unattended AOBP measurements result in slightly lower readings than attended AOBP.”

Source: [Deragon et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826897/)

<a id="topic-3.1.1.6.1-7"></a>

###### Blood pressure as the basis of benefit in FDA labeling guidance

> “However, blood pressure control is well established as beneficial in preventing serious cardiovascular events, and inadequate treatment of hypertension is acknowledged as a significant public health problem.”
> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “This observation has led us to conclude that the general, qualitative claim of cardiovascular outcome benefits pertains to all classes of antihypertensive drugs.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.1.6.1-8"></a>

###### Blood pressure in the FDA table of surrogate endpoints

| Disease or use | Patient population | Surrogate endpoint | Type of approval appropriate for |
| --- | --- | --- | --- |
| “Hypertension” | “Patients with hypertension” | “Blood pressure” | “Traditional” |

Source: [FDA Table of Surrogate Endpoints (2026)](https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure)

<a id="topic-3.1.1.6.1-9"></a>

###### Studies on a background of multiple antihypertensive drugs in FDA draft guidance

> “Drugs that lower blood pressure have been shown to reduce these risks”
> “Although FDA will not label a drug with a specific claim for resistant”
> “FDA does believe that drugs could be shown to be effective in treating”
> “Demonstrate superiority to placebo in reducing blood pressure in hypertensive patients on”
> “appropriate doses of three or more antihypertensive drugs with different mechanisms of”

Source: [FDA draft guidance, studies on a background of multiple antihypertensive drugs (2018)](https://www.fda.gov/media/114731/download)

<a id="topic-3.1.1.6.1-10"></a>

###### Cardiovascular risk reduction per 5 mm Hg lower systolic blood pressure

> “In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.1.6.1-11"></a>

###### Key secondary endpoint: office systolic blood pressure below 130 mm Hg

> “The overarching blood pressure treatment goal is <130/80 mm Hg for all adults, with additional considerations for those who require institutional care, have a limited predicted lifespan, or are pregnant.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.1.6.1-12"></a>

###### Key secondary endpoint: participants taking 3 or more antihypertensive medications

> “Resistant hypertension is defined as BP above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses or BP at goal but requiring ≥4 medications”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.1.6.1-13"></a>

###### Key secondary endpoint: obesity and aldosterone dysregulation

> “There is increasing awareness that primary aldosteronism and the secondary causes of increased aldosterone production, including obesity and aldosterone breakthrough, contribute significantly to elevated BP and a lack of BP control among patients with hypertension.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-14"></a>

###### Multiplicity hierarchy of the primary and secondary hypotheses

> “A graphical testing approach was used to control multiplicity for the secondary efficacy outcomes (eFigure 2 in Supplement 1). The CIs for the secondary outcomes were adjusted for multiplicity.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-15"></a>

###### Prespecified adverse events of special interest

> “Safety was assessed as the proportion of participants having received at least 1 dose of trial medication experiencing any treatment-emergent adverse events. Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Sample size calculation and power

> “The sample size of 1000 participants randomized to 1 of 3 treatment groups in a 1:2:1 ratio had 95% power to detect a difference of 3.7 mm Hg in office systolic BP between lorundrostat (n = 750) and placebo (n = 250) at a 1-sided α level of .025, assuming a common SD of 14 mm Hg for change in office systolic BP. This sample size allowed robust safety monitoring.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 1083”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.7.1-3"></a>

###### Participants randomized and dosed by group

> “Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants in the primary analysis

> “The data for lorundrostat were pooled (n = 808) and included the 538 participants from the 50-mg only group plus the 270 participants in the 50-mg dose group with the 100-mg escalation option.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.1-5"></a>

###### Participants in the responder analysis

> “A total of 790 participants in the lorundrostat 50 mg (N=524) or placebo (N=266) groups were included in the analysis”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.7.1-6"></a>

###### Participants in the chronic kidney disease analysis

> “This analysis included 808 participants with uHTN concurrently receiving >2 BP lowering medications who received either once daily LOR 50mg (N=538) or placebo (PBO) (N=270) in the Launch-HTN trial.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

> “The analysis evaluated the efficacy and safety of once-daily lorundrostat 50 mg by CKD status among 800 participants with uncontrolled or resistant hypertension enrolled in the randomized, double-blind, placebo-controlled Phase 3 Launch-HTN trial.”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Intention-to-treat and safety populations

> “Included participants who received at least 1 dose of trial drug according to treatment assignment at randomization.”
> “Included participants who received at least 1 dose of trial drug according to the actual treatment they received.”
> “Participant Demographics and Characteristics at Randomization (Baseline) in the Intention-to-Treat Population.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.2-2"></a>

###### Primary estimand and analysis model

> “The primary estimand followed the treatment policy approach by using all observed efficacy data regardless of possible treatment discontinuation. The primary outcome was analyzed on 1000 multiple imputed data using analysis of covariance with categorical factors for treatment, geographic region or country (randomization stratification factor), and treatment interaction with geographic region or country and using baseline office systolic BP as a covariate. Canada and the US were merged into 1 geographic stratum because only 3 participants were randomized in Canada.”
> “The secondary outcomes were analyzed on multiple imputed data using the analysis methods described in eTable 2 in Supplement 1.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.2-3"></a>

###### Intercurrent events and handling of missing data

> “Intercurrent events (IC) leading to the discontinuation of the study treatment were identified by an independent committee. Adjudications were performed prior to the database lock and unblinding.”
> “Missing data in participants with ICE due to AE were considered missing not at random (MNAR) and were multiply imputed using the Treatment Policy ("retrieved dropouts") imputation approach”
> “Missing data due to death was multiply imputed by using 5% worst outcome.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.7.2-4"></a>

###### Analysis of the obesity and within-participant secondary hypotheses

> “The test is for the difference in slopes between the lorundrostat and placebo.”
> “A paired t-test comparing the value at baseline and value at Week 12.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Sensitivity analyses of the primary endpoint

> “Values for all participants with intercurrent events after the occurrence of intercurrent event were treated as missing at random.”
> “Values for all participants with missing data regardless of cause were treated as Missing Not at Random (MNAR) and were assumed to trend with placebo distribution.”
> “No imputation was performed; the analysis used observed data only.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.7.2-6"></a>

###### Population of the responder analysis

> “In this secondary analysis, we included participants in the 50 mg lorundrostat or placebo groups with AOSBP ≥130 mmHg at baseline. Adjusted odds ratio of achieving SBP <130 mmHg at week 12 was analyzed in multiply imputed datasets using a treatment policy approach.”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.7.2-7"></a>

###### Definition of chronic kidney disease in the subgroup analysis

> “CKD was defined as eGFR <60mL/min/1.73m2 or UACR ≥30mg/g.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

> “Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Screening, run-in, randomization, and dosing

> “Between November 24, 2023, and September 16, 2024, 3161 participants were screened, 1575 entered the placebo-run in phase, and 1083 were randomized to the double-blind treatment phase”
> “Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.1-2"></a>

###### Most frequent reasons for exclusion

> “The most frequent reasons were current use of treatment (or anticipated treatment) with any of the prohibited medications described in the trial protocol within a specified time frame (n = 15); had a condition that would preclude participation in the study (based on the opinion of the investigator) (n = 14); and had current, known, or presumed orthostatic hypotension (n = 9).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.1-3"></a>

###### Escalation to 100 mg at week 6

> “Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.1-4"></a>

###### Intercurrent events and missing data

> “Altogether, there were 24 intercurrent events (ICE), 23 due to treatment discontinuation for AEs and one for death. Of these, 10/1078 (0.9%) were missing data at Week 6 for AE, and 13 were not missing Week 6 data. At Week 12, 12/1078 (1.1%) were missing data for AE, 1/1078 (0.1%) due to death and 12 completed the trial ("retrieved dropouts").”
> “Remaining missing data (56/1078, 5.2%) at Week 6 and (67/1078, 6.2%) at Week 12 were considered missing at random (MAR) and were multiply imputed following the distribution in the group to which they were randomized.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.1-5"></a>

###### Enrollment of lorundrostat-treated participants in the open-label extension

> “Of the 808 participants from Launch-HTN's lorundrostat treatment arms, 632 participants were eligible and enrolled in Transform-HTN.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic summary of the randomized population

> “Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more.”
> “The randomized groups were comparable for the baseline demographic and clinical characteristics (Table 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.2-2"></a>

###### Baseline characteristics by randomized group

| Characteristic | Lorundrostat 50 mg then 100 mg (n = 270) | Lorundrostat 50 mg (n = 541) | Placebo (n = 272) |
| --- | --- | --- | --- |
| Age, mean (SD), y | “61.4 (10.3)” | “61.7 (10.6)” | “61.8 (10.4)” |
| Male, No. (%) | “142 (52.6)” | “294 (54.3)” | “139 (51.1)” |
| Female, No. (%) | “128 (47.4)” | “247 (45.7)” | “133 (48.9)” |
| Asian, No. (%) (lorundrostat n = 267 and n = 535) | “4 (1.5)” | “14 (2.6)” | “6 (2.2)” |
| Black or African American, No. (%) (lorundrostat n = 267 and n = 535) | “72 (26.7)” | “152 (28.1)” | “87 (32.0)” |
| White, No. (%) (lorundrostat n = 267 and n = 535) | “190 (70.4)” | “366 (67.7)” | “177 (65.1)” |
| Hispanic or Latino ethnicity, No. (%) | “102 (37.8)” | “191 (35.3)” | “101 (37.1)” |
| Body mass index, mean (SD) | “32.8 (6.7)” | “33.0 (6.9)” | “32.6 (7.4)” |
| Body mass index ≥30 (obesity), No. (%) | “166 (61.5)” | “351 (64.9)” | “168 (61.8)” |
| eGFR at randomization, mean (SD), mL/min/1.73 m2 | “92.8 (17.6)” | “90.1 (17.8)” | “91.2 (16.4)” |
| eGFR ≥60 mL/min/1.73 m2, No. (%) | “255 (94.4)” | “500 (92.9)” | “260 (96.3)” |
| Diabetes, No. (%) | “76 (28.2)” | “173 (32.2)” | “89 (33.0)” |
| Taking 2 antihypertensive medications, No. (%) | “106 (39.3)” | “213 (39.4)” | “113 (41.5)” |
| Taking ≥3 antihypertensive medications, No. (%) | “164 (60.7)” | “328 (60.6)” | “159 (58.5)” |
| Thiazide or thiazide-like diuretic, No. (%) | “259 (95.9)” | “520 (96.1)” | “259 (95.2)” |
| ACE inhibitor or ARB, No. (%) | “237 (87.8)” | “467 (86.3)” | “225 (82.7)” |
| Calcium channel blocker, No. (%) | “140 (51.9)” | “278 (51.4)” | “135 (49.6)” |
| Glucagon-like peptide-1 receptor agonists, No. (%) | “13 (4.8)” | “30 (5.6)” | “9 (3.3)” |
| Sodium-glucose cotransporter 2 inhibitors, No. (%) | “14 (5.2)” | “21 (3.9)” | “13 (4.8)” |
| Systolic blood pressure, mean (SD), mm Hg | “146.6 (11.1)” | “149.0 (12.2)” | “148.8 (12.2)” |
| Systolic blood pressure <140 mm Hg, No. (%) | “83 (30.7)” | “137 (25.3)” | “73 (26.8)” |
| Systolic blood pressure 140 to <160 mm Hg, No. (%) | “152 (56.3)” | “294 (54.3)” | “144 (52.9)” |
| Systolic blood pressure ≥160 mm Hg, No. (%) | “35 (13.0)” | “110 (20.3)” | “55 (20.2)” |
| Diastolic blood pressure, mean (SD), mm Hg | “86.3 (9.2)” | “87.8 (9.0)” | “87.1 (9.1)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.2-3"></a>

###### Baseline characteristics of the responder analysis population

> “(mean age, 61.9 years; 47.1% female; 29.6% Black; 63.8% BMI ≥30 kg/m2; mean SBP, 149.4 mmHg; 60.1% using ≥3 AHTs)”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.8.2-4"></a>

###### Baseline characteristics of participants with chronic kidney disease

> “Among participants with CKD (n=192), 71% were receiving three or more anti-hypertensive medications at baseline, compared with 56% of those without CKD. In addition, 31% of participants with CKD had systolic blood pressure (SBP) ≥160 mmHg at baseline, versus 17% of participants without CKD.”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Primary endpoint: change in office systolic blood pressure at week 6

> “The least-squares mean change in office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) for the pooled 50 mg of lorundrostat group vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares between-group mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg], P < .001; Table 2 and Figure 2).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-2"></a>

###### Primary, secondary, and prespecified exploratory blood pressure outcomes

| Outcome | Lorundrostat baseline, mean (SD) | Lorundrostat follow-up, mean (SD) | Lorundrostat least-squares mean change (95% CI) | Placebo baseline, mean (SD) | Placebo follow-up, mean (SD) | Placebo least-squares mean change (95% CI) | Least-squares mean difference (95% CI) | P value |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Primary: systolic BP, baseline to 6 wk (pooled lorundrostat n = 808; placebo n = 270) | “148.2 (11.9)” | “133.6 (15.3)” | “−16.9 (−19.0 to −14.9)” | “148.6 (12.1)” | “140.7 (15.0)” | “−7.9 (−11.5 to −4.2)” | “−9.1 (−13.3 to −4.9)” | “<.001” |
| Secondary: systolic BP <130 mm Hg at 6 wk, No. (%); difference as odds ratio (95% CI) | “20 (2.5)” | “356 (44.1)” | “NA” | “NA” | “65 (24.1)” | “NA” | “3.4 (1.5 to 7.8)” | “.003” |
| Secondary: taking 2 antihypertensive drugs, 6 wk (lorundrostat n = 318; placebo n = 112; 97.5% CI where reported) | “147.6 (11.5)” | “134.2 (14.9)” | “−16.1 (−19.1 to −13.0)” | “148.0 (11.3)” | “141.4 (14.4)” | “−7.2 (−11.7 to −2.8)” | “−8.8 (−14.8 to −2.9)” | “<.001” |
| Secondary: taking ≥3 antihypertensive drugs, 6 wk (lorundrostat n = 490; placebo n = 158; 97.5% CI) | “148.6 (12.1)” | “133.2 (15.6)” | “−17.2 (−19.6 to −14.7)” | “149.0 (12.6)” | “140.4 (15.5)” | “−8.1 (−12.4 to −3.8)” | “−9.0 (−14.0 to −4.1)” | “<.001” |
| Secondary: systolic BP, baseline to 12 wk, escalated dose group (lorundrostat n = 270) | “146.6 (11.1)” | “131.9 (14.3)” | “−15.7 (−19.3 to −12.2)” | “148.6 (12.1)” | “141.2 (15.4)” | “−7.3 (−11.1 to −3.5)” | “−8.4 (−13.6 to −3.2)” | “.002” |
| Secondary: within-participant analysis, 12 wk (n = 92; 97.5% CI) | “148.3 (12.4)” | “138.1 (14.8)” | “−10.2 (−14.3 to −6.1)” | “NA” | “NA” | “NA” | “NA” | “<.001” |
| Exploratory: diastolic BP, baseline to 6 wk | “87.3 (9.1)” | “79.9 (10.4)” | “−8.6 (−9.9 to −7.3)” | “87.1 (9.0)” | “83.2 (10.1)” | “−5.2 (−7.4 to −3.0)” | “−3.4 (−5.9 to −0.8)” | “.01” |
| Exploratory: systolic BP, baseline to 12 wk, 50 mg group (lorundrostat n = 538) | “149.1 (12.2)” | “132.5 (16.0)” | “−19.0 (−21.6 to −16.3)” | “148.6 (12.1)” | “141.2 (15.4)” | “−7.3 (−11.1 to −3.5)” | “−11.6 (−16.3 to −7.0)” | “<.001” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-3"></a>

###### Observed proportion with office systolic blood pressure below 130 mm Hg at week 6

> “The estimated proportions are based on multiple imputed data. The observed data were 332/755 (44.0%) for lorundrostat vs 62/257 (24.1%) for placebo.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-4"></a>

###### Key secondary endpoints at week 6

> “An office systolic BP of less than 130 mm Hg at week 6 was achieved by 44.1% of participants in the pooled 50 mg of lorundrostat group vs 24.1% of participants in the placebo group (odds ratio, 3.4 [95% CI, 1.5 to 7.8]; P = .003).”
> “Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications. Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.”
> “A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-5"></a>

###### Key secondary endpoints at week 12 with escalation to 100 mg

> “Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −8.4 mm Hg (95% CI, −13.6 to −3.2 mm Hg; P = .002) for participants randomized to 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks. Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −10.2 mm Hg (97.5% CI, −14.3 to −6.1 mm Hg; P < .001) for the 92 participants who escalated from 50 mg of lorundrostat to 100 mg.”
> “Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-6"></a>

###### Subgroup consistency of the primary endpoint

> “The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-7"></a>

###### Prespecified exploratory endpoints: diastolic blood pressure at week 6 and systolic blood pressure at week 12

> “Placebo-adjusted least squared mean change in AODBP at Week 6 was -3.4 mmHg (95% CI, - 5.9 to -0.8, p=0.01).”
> “The AOSBP reduction observed with lorundrostat 50 mg at Week 6 was maintained at Week 12 with LSM (SE) change in AOSBP of -19.0 (1.4) mmHg for lorundrostat 50mg and -7.3 (1.95) mmHg for placebo (placebo-adjusted LSM change of -11.6 mmHg; 95% CI, -16.3 to -7.0, p<0.001).”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.3-8"></a>

###### Sensitivity analyses of the primary endpoint

| Analysis | Lorundrostat LS mean (SE) | Placebo LS mean (SE) | LS mean difference (SE) | 95% CI of LS mean difference | P value |
| --- | --- | --- | --- | --- | --- |
| Sensitivity analysis 1: intercurrent events treated as missing at random (lorundrostat n = 808; placebo n = 270) | “-16.9 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |
| Sensitivity analysis 2: all missing data treated as missing not at random (lorundrostat n = 808; placebo n = 270) | “-16.5 (1.1)” | “-7.9 (1.9)” | “-8.6 (2.2)” | “-12.2 to -4.4” | “<0.001” |
| Sensitivity analysis 4: observed data only (lorundrostat n = 755; placebo n = 257) | “-17.0 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.3-9"></a>

###### Tipping point sensitivity analysis

> “There was no tipping point within maximum prespecified increment of +40 mmHg/-40 mmHg”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.3-10"></a>

###### Week 6 and week 12 results in the topline announcement, March 2025

> “Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6”
> “Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at end of treatment, week 12”
> “The change in blood pressure in response to lorundrostat in subjects using two background antihypertensives (uncontrolled) or three to five (resistant) were similar, and both were statistically significantly different from the response in those taking placebo.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.1.8.3-11"></a>

###### Week 12 placebo-adjusted result in the annual report

> “The Launch-HTN global Phase 3 trial demonstrated a statistically significant and clinically meaningful 11.6 mmHg placebo-adjusted”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-3.1.1.8.3-12"></a>

###### Responder analysis: office systolic blood pressure below 130 mm Hg and reductions of 5, 10, and 20 mm Hg at week 12

> “The guideline-recommended target of AOSBP <130 mmHg at week 12 was achieved by 46.3% and 19.9% of participants in the lorundrostat and placebo groups, respectively (odds ratio, 3.86; 95% CI, 2.66-5.60; P<0.0001;”
> “At week 12, 79%, 70%, and 41% of participants treated with lorundrostat had an SBP reduction of ≥5 mmHg, ≥10 mmHg, and ≥20 mmHg, respectively.”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

> “showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg.”

Source: [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="topic-3.1.1.8.3-13"></a>

###### Participants with and without chronic kidney disease: systolic blood pressure and albuminuria at week 12

> “Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively (Table). Placebo-adjusted percent change in geometric mean UACR in LOR 50mg participants with baseline albuminuria at week 12 was -52.2% (95% CI, -64.0 to -36.6; P<0.001).”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-3.1.1.8.3-14"></a>

###### Participants with and without chronic kidney disease: results by stage

| CKD stage (placebo N; lorundrostat 50 mg N) | Placebo AOSBP LSM (95% CI) change at week 12 | Lorundrostat 50 mg AOSBP LSM (95% CI) change at week 12 | Placebo adjusted (95% CI) | Placebo week 12 % with AOSBP <130 mmHg | Lorundrostat 50 mg week 12 % with AOSBP <130 mmHg |
| --- | --- | --- | --- | --- | --- |
| No CKD (202; 406) | “-7.2 (-11.3, -3.2)” | “-19.4 (-22.2, -16.6)” | “-12.2 (-17.1, -7.3)” | “22.1” | “48.0” |
| Stage 1 (30; 58) | “-8.9 (-15.4, -2.3)” | “-19.5 (-24.1, -14.9)” | “-10.6 (-18.6, -2.6)” | “18.4” | “50.6” |
| Stage 2 (25; 31) | “-9.1 (-15.9, -2.4)” | “-16.7 (-22.6, -10.8)” | “-7.6 (-16.5, 1.4)” | “12.0” | “28.4” |
| Stage 3 (10; 38) | “-8.5 (-18.1, 1.1)” | “-18.5 (-24.1, -13.0)” | “-10.1 (-21.1, 1.0)” | “30.0” | “47.0” |

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-3.1.1.8.3-15"></a>

###### Participants with chronic kidney disease: P values and albuminuria population

> “At week 12, placebo-adjusted SBP reductions were 9.6 mmHg in participants with CKD (p=0.0022) and 12.2 mmHg in those without CKD (p<0.0001). A greater proportion of lorundrostat-treated participants also achieved target SBP of <130 mmHg at week 12 compared with placebo, both among CKD participants (44% vs 18%) and non-CKD participants (48% vs 22%).”
> “Lorundrostat treatment was also associated with a significant placebo-adjusted reduction in urinary albumin-to-creatinine ratio (UACR) among 84 participants with CKD and baseline albuminuria, achieving a 52.2% placebo-adjusted reduction at 12 weeks (p<0.0001).”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Adverse events by randomized group

| Event, No. (%) | Lorundrostat 50 mg then 100 mg (n = 270) | Lorundrostat 50 mg (n = 538) | Placebo (n = 270) |
| --- | --- | --- | --- |
| Died | “0” | “0” | “1 (0.4)” |
| Serious adverse event | “2 (0.7)” | “12 (2.2)” | “8 (3.0)” |
| Treatment-emergent adverse event, severe | “6 (2.2)” | “9 (1.7)” | “8 (3.0)” |
| Treatment-emergent adverse event, moderate | “30 (11.1)” | “100 (18.6)” | “31 (11.5)” |
| Treatment-emergent adverse event, mild | “115 (42.6)” | “180 (33.5)” | “59 (21.9)” |
| Special interest: severely elevated blood pressure | “2 (0.7)” | “10 (1.9)” | “11 (4.1)” |
| Special interest: hypotension with symptoms | “5 (1.9)” | “11 (2.0)” | “1 (0.4)” |
| Special interest: hyperkalemia | “7 (2.6)” | “11 (2.0)” | “1 (0.4)” |
| Special interest: hyponatremia | “28 (10.4)” | “37 (6.9)” | “9 (3.3)” |
| Special interest: glucocorticoid deficiency | “0” | “0” | “3 (1.1)” |
| Special interest: reduction in estimated glomerular filtration rate | “9 (3.3)” | “16 (3.0)” | “2 (0.7)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-2"></a>

###### Overall adverse events, serious adverse events, and deaths

> “Treatment-emergent adverse events were experienced by 49.9% of participants (538/1078) and were mostly mild or moderate in severity (Table 3). Serious adverse events occurred in 22 participants and included 1 event that was considered to be related to treatment. One participant in the placebo group died after week 6 (unrelated to treatment).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-3"></a>

###### Definitions used in the adverse event table

> “Defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg.”
> “Trial drug had to be modified due to the adverse event (dose reduction, interruption, or discontinuation).”
> “Confirmed by adrenocorticotropic hormone (cosyntropin or regional equivalent) stimulation test; trial drug was discontinued.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-4"></a>

###### Serum potassium above 6.0 mmol/L

> “A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo (eTable 4 in Supplement 1). The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range (eFigure 5 in Supplement 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-5"></a>

###### Serum sodium and potassium thresholds by randomized group

| Level, n (%) | Lorundrostat 50 to 100 mg daily (n=270) | Lorundrostat 50 mg (n=538) | Placebo (n=270) |
| --- | --- | --- | --- |
| Serum sodium <132 mmol/L | “22 (8.1)” | “38 (7.1)” | “13 (4.8)” |
| Serum sodium <130 mmol/L | “11 (4.1)” | “14 (2.6)” | “4 (1.5)” |
| Serum sodium <125 mmol/L | “4 (1.5)” | “4 (0.7)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, single value | “29 (10.7)” | “38 (7.1)” | “3 (1.1)” |
| Serum potassium 6.1 to 6.5 mmol/L, single value | “2 (0.7)” | “5 (0.9)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, single value | “2 (0.7)” | “1 (0.2)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, confirmed | “24 (8.9)” | “31 (5.8)” | “2 (0.7)” |
| Serum potassium 6.1 to 6.5 mmol/L, confirmed | “2 (0.7)” | “3 (0.6)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, confirmed | “1 (0.4)” | “0” | “0” |

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Counting rules for the sodium and potassium table

> “Number of participants with at least one clinical laboratory report meeting the corresponding level at any laboratory during the double-blind treatment period. A participant is included only in the highest level observed.”
> “These confirmatory measurements were performed to account for cases of factitious hyperkalemia such as hemolyzed samples. Participants were counted if repeat value obtained on study drug confirmed potassium level ≥5.6 mmol/L.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.5-7"></a>

###### Confirmed hyperkalemia reported by the company

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 1.1% and 1.5% in the 50 mg and 50 to 100 mg arms, respectively.”
> “After exclusion of the spurious results, the incidence of confirmed hyperkalemia was 0.6% and 1.1% in the 50 mg and 50 to 100 mg arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “A confirmed serum potassium level of greater than 6.0 mmol/L occurred in three subjects (0.6%) on lorundrostat 50 mg once daily, as compared to one subject (0.4%) on placebo.”

Source: [Mineralys Therapeutics press release, Launch-HTN JAMA publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american)

<a id="topic-3.1.1.8.5-8"></a>

###### Kidney function: creatinine-based and cystatin C-based eGFR

> “Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.”
> “The observed decline in eGFR (assessed using the cystatin C–based eGFR formula to correct for falsely elevated creatinine due to competition between lorundrostat and creatinine for MATE [multidrug and toxin extrusion] 1–dependent transport) after initiation of lorundrostat was expected.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-9"></a>

###### Cortisol and glucocorticoid insufficiency

> “At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.”
> “The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group. No participants treated with lorundrostat experienced a glucocorticoid deficiency (confirmed by stimulation testing; Table 3). There were no reports of hyperadrenocorticism.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-10"></a>

###### Treatment discontinuation due to hyperkalemia, hyponatremia, or reduced kidney function

> “Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR). Among participants in the placebo group, there were no treatment discontinuations due to hyperkalemia, hyponatremia, or reduction in kidney function.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-11"></a>

###### Serious adverse events reported in the topline announcement

> “In the Launch-HTN trial there were 12 subjects (2.2%) and two subjects (0.7%) with treatment-emergent serious adverse events (SAEs) in the 50 mg and 50 mg with optional dose escalation to 100 mg arms, respectively, compared with eight subjects (3.0%) in the placebo arm. There was only one subject (0.1%) in the trial with treatment-related SAEs that occurred in the 50 mg arm.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.1.8.5-12"></a>

###### Confirmed hyperkalemia and symptomatic hypotension in the responder analysis

> “In the lorundrostat 50 mg and placebo groups, 3 (0.6%) and 1 (0.4%) participants had confirmed serum potassium >6.0 mmol/L, respectively. Symptomatic hypotension was reported in 11 (2.0%) participants in the lorundrostat 50 mg group and 1 (0.4%) in the placebo group.”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.8.5-13"></a>

###### Participants with chronic kidney disease: potassium and cystatin C-based eGFR

> “Among participants receiving LOR 50mg, confirmed serum potassium >6.0 mmol/L occurred in 3 (2.4%) CKD participants and in none of the non-CKD participants. In LOR 50mg participants, mean cystatin C-based eGFR decreased by 7.3, 4.0 and 4.2 mL/min/1.73 m2 in those with CKD stage 1, 2, and 3, respectively, compared with 2.1 mL/min/1.73 m2 in those without CKD.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: study limitations

Launch-HTN randomized 1,083 participants and compared lorundrostat with placebo for 12 weeks, a duration the investigators describe as “consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration”. Longer-term data come from the open-label extension, which enrolled 632 of the 808 participants who received lorundrostat in Launch-HTN. The trial had no active comparator. The primary endpoint, unattended automated office systolic blood pressure at week 6, was chosen “to reflect usual clinical practice”; the investigators note that ambulatory measurement “is the gold standard for assessment of BP”. FDA guidance attributes the cardiovascular benefits of antihypertensive drugs largely to the decrease in blood pressure, and the trial did not measure cardiovascular outcomes.

In the escalation group, 92 of 270 participants (34.1%) met the week 6 criteria and received 100 mg, and the investigators conclude that the higher dose “provided no additional benefit” to participants who had not reached goal on 50 mg; the week 12 placebo-adjusted difference in the escalation group (−8.4 mm Hg) was smaller than in the 50 mg group (−11.6 mm Hg). Two week 12 values are reported for the 50 mg group: −11.6 mm Hg in the publication and 11.7 mm Hg in the March 2025 topline announcement.

Eligibility excluded people with eGFR below 45 mL/min/1.73 m2, serum potassium above 5.0 mmol/L at screening or above 4.8 mmol/L at randomization, serum sodium below 135 mmol/L, or heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months, and prohibited mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and potassium-sparing diuretics. Of the 1,083 participants, 685 (63.3%) had obesity and 432 (39.9%) were taking 2 antihypertensive medications, so the population includes people who would not meet the 2025 AHA/ACC definition of resistant hypertension. Three participants were randomized in Canada. The publication reports 159 sites in 13 countries, while the registry lists 184 locations. Hyperkalemia rates depend on the definition: a single serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, while the company reports confirmed hyperkalemia of 1.1% and 0.6%, respectively. The responder analysis is described as a “secondary analysis” and the chronic kidney disease analysis as a “Post hoc analysis”; both are published as conference abstracts. No health-related quality of life or patient-reported outcome was reported. The sponsor's chief medical officer and lead statistician are listed among the sponsor leadership of the trial and are authors of the publication.

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf); [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693); [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from); [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results); [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm); [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download); [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461); [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="topic-3.1.1.9-2"></a>

###### Limitations stated by the investigators

> “This trial has limitations. First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.”
> “Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice. Importantly, the phase 2 Advance-HTN trial18 of lorundrostat used 24-hour ambulatory BP measurements and, compared with placebo, demonstrated similar patterns of BP lowering after 12 weeks of treatment.”
> “Third, the current trial compared the efficacy of lorundrostat vs placebo, but the trial did not include an active comparator.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.9-3"></a>

###### Out-of-office measurement and cardiovascular risk prediction

> “both home BP and 24-hour ABPM are shown to be superior to office BP in predicting cardiovascular events.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.1.9-4"></a>

###### Sponsor leadership of the trial

> “Mineralys Therapeutics, Inc (Sponsor Leadership): David Rodman, MD (Chief Medical Officer); Branko Kopjar MD (Lead Statistician); Jessica Ibbitson (Senior Vice President, Clinical Operations)”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="heading-3.1.2"></a>

#### 3.1.2 Advance-HTN

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.1-2"></a>

###### Objective stated in the trial presentation

> “Assess the 24-hour blood pressure lowering effect of lorundrostat taken once daily in participants with uncontrolled and treatment-resistant hypertension on a standardized antihypertensive regimen”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.1-3"></a>

###### Target population stated by the company

> “The trial was designed to evaluate lorundrostat in an uncontrolled or resistant hypertensive population at the highest risk and which would normally be treated by a specialist given severity of their condition.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-03-13”
> “Primary Completion (Actual) 2025-01-15”
> “Study Completion (Actual) 2025-01-15”
> “First Posted 2023-03-15”
> “Last Update Posted 2026-01-20”
> “Completed”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.2-2"></a>

###### Number and country of locations in the ClinicalTrials.gov record

> “This study has 104 locations”
> “United States”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.2-3"></a>

###### Number of sites stated in the trial presentation

> “Multicenter (103 sites in the United States)”
> “103 Sites throughout the United States”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.2-4"></a>

###### Topline results announced in March 2025

> “RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE)”
> “today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.2.2-5"></a>

###### Presentation at the American College of Cardiology Scientific Session in March 2025

> “detailed results from Advance-HTN were presented in a late-breaking session at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) on Saturday, March 29, 2025, at 1:30 p.m. CT.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.2-6"></a>

###### Publication in April 2025

> “today announced that the New England Journal of Medicine (NEJM) published the detailed results from the Company’s pivotal Phase 2 Advance-HTN trial”
> “is featured in the April 23, 2025 issue of NEJM.”

Source: [Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Official title and design in the ClinicalTrials.gov record

> “A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Medication Regimen”
> “The study consists of a standardized AHT regimen run-in period followed by a randomized, double-blind, placebo-controlled, parallel arm period. Following the double-blind period subjects may be offered the opportunity to participate in an open-label extension (OLE) study. Subjects electing to not participate in the OLE will undergo an end of study (EoS) visit approximately 2 weeks after the last dose of study drug to complete their participation in the study.”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.3-2"></a>

###### Design features stated in the trial presentation

> “Multicenter (103 sites in the United States)”
> “Prospective”
> “Randomized”
> “Double-blind”
> “Placebo-controlled”
> “Parallel group”
> “Phase 2b trial”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.3-3"></a>

###### Trial periods and their durations in the trial presentation

| Period | Quoted record |
| --- | --- |
| Screening | “2 weeks” |
| Single-blind run-in on the standardized regimen | “3 weeks” |
| Randomized double-blind treatment | “12 weeks” |
| After the end of treatment | “Open-label extension”; “2-week end of study visit”; “4-week washout” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Design stated in the publication abstract

> “In this multicenter, double-blind, randomized, placebo-controlled trial, we assigned participants who were receiving two to five antihypertensive medications and had a blood-pressure measurement of 140/90 mm Hg or higher obtained during an office visit to undergo a standardized antihypertensive regimen for 3 weeks.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.3-5"></a>

###### Role in the pivotal program stated by the company

> “today announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat in patients with confirmed uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

> “This includes two pivotal, registrational trials, the Phase 3 Launch-HTN trial and Phase 2 Advance-HTN trial”
> “Advance-HTN evaluated the efficacy and safety of lorundrostat for the treatment of confirmed uHTN or rHTN when used as add-on therapy to a standardized, optimized, and adherent background treatment of two or three antihypertensive medications.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “At least 18 years of age at the time of signing the informed consent form”
> “At Screening: AOBP SBP of 140-180 mmHg and AOBP DBP of 65-110 mmHg, or AOBP DBP of 90-110 mmHg”
> “24-hour average ABPM SBP of 130-180 mmHg or 24-hour average ABPM DBP >80 mmHg”
> “Taking between 2 and 5 AHT medications, inclusive, at Screening visit.”
> “BMI of 18-40 kg/m2 inclusive at Screening”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “eGFR <45 mL/min/1.73 m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula”
> “Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization”
> “Serum sodium <135 mmol/L at Screening”
> “History of heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months prior to Screening.”
> “Diabetes mellitus with a glycosylated hemoglobin (HbA1c) >9% (>74.9 mmol/mol) at Screening”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.4-3"></a>

###### Age, sex, and healthy volunteers in the ClinicalTrials.gov record

> “18 Years and older”
> “Sexes Eligible for Study All”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.4-4"></a>

###### Blood pressure, medication, and laboratory thresholds in the trial presentation

| Criterion | Quoted record |
| --- | --- |
| Background antihypertensive medications at screening | “2 - 5 BP medications” |
| Office blood pressure at screening | “SBP 140 to 180 mm Hg, or DBP 90 to 110 mm Hg” |
| 24-hour ambulatory blood pressure before randomization | “SBP 130 to 180 mm Hg, or DBP > 80 mm Hg” |
| Serum sodium | “Na+ ≥ 135” |
| Estimated glomerular filtration rate | “eGFR ≥ 45” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.4-5"></a>

###### Eligibility for randomization after the standardized regimen in the publication abstract

> “Subsequently, participants with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were assigned to receive placebo”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Standardized antihypertensive regimen during the run-in

> “Switch to standardized regimen:”
> “Indapamide 2.5 mg daily or HCTZ 25 mg daily”
> “Olmesartan 40 mg daily”
> “+/- Amlodipine 10 mg daily”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.5-2"></a>

###### Standardized regimen assigned by the number of prior medications

> “Subjects who meet screening criteria had their existing hypertension medications discontinued and start on a standard regimen of an angiotensin II receptor blocker (ARB) and a diuretic, if previously on two medications, or a standard regimen of ARB, diuretic and calcium channel blocker if previously on three to five medications.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.5-3"></a>

###### Randomized treatment arms in the ClinicalTrials.gov record

| Arm | Quoted record |
| --- | --- |
| Placebo comparator | “Placebo once daily for 12 weeks” |
| Experimental: Dose 1 | “lorundrostat Dose 1 once daily for 12 weeks” |
| Experimental: Dose 2 | “lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria” |

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.5-4"></a>

###### Doses and dose-adjustment rule in the publication abstract

> “assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.5-5"></a>

###### Treatment duration and titration stated by the company

> “Subjects who remained hypertensive despite the standardized regimen were then randomized into three cohorts and treated for twelve weeks: lorundrostat 50 mg once-daily (QD), lorundrostat 50 mg QD and an option to titrate to 100 mg QD at week four based on defined criteria, or placebo.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Change in 24-hour Ambulatory Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Registered primary outcome measure in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP)” | “Baseline (Randomization) to Week 12” |

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary end point defined in the publication abstract

> “The primary end point was the change in 24-hour average systolic blood pressure from baseline to week 12, assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.6.1-3"></a>

###### Ambulatory blood pressure monitoring as the reference measurement, stated by the lead investigator

> “Twenty-four-hour ambulatory blood pressure monitoring is the gold standard for assessing the true impact of an antihypertensive therapy, as it provides a more comprehensive picture of blood pressure control beyond the office setting, including overnight readings,”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.6.1-4"></a>

###### Ambulatory and clinic blood pressure as predictors of mortality

> “Ambulatory blood pressure provides a more comprehensive assessment than clinic blood pressure, and has been reported to better predict health outcomes than clinic or home pressure.”
> “After adjustment for clinic blood pressure, 24-h blood pressure remained strongly associated with all-cause deaths (HR 1·43 [95% CI 1·37-1·49]), but the association between clinic blood pressure and all-cause death was attenuated when adjusted for 24-h blood pressure (1·04 [1·00-1·09]).”
> “Ambulatory blood pressure, particularly night-time blood pressure, was more informative about the risk of all-cause death and cardiovascular death than clinic blood pressure.”

Source: [Staplin et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37156250/)

<a id="topic-3.1.2.6.1-5"></a>

###### Out-of-office blood pressure in the 2025 AHA/ACC guideline

> “both home BP and 24-hour ABPM are shown to be superior to office BP in predicting cardiovascular events.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.2.6.1-6"></a>

###### Blood pressure reduction as the basis of cardiovascular benefit

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.2.6.1-7"></a>

###### Same primary endpoint in a phase 3 trial of another aldosterone synthase inhibitor

> “The primary endpoint was change in 24 h ambulatory SBP from baseline to week 12, assessed by analysis of covariance in patients administered at least one dose of study medication with valid ambulatory SBP measurement at baseline and week 12.”

Source: [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)

<a id="topic-3.1.2.6.1-8"></a>

###### Key secondary end points in the trial presentation

> “Change in 24-hour average systolic blood pressure from baseline to week 4”
> “Proportion of participants with 24-hour average systolic blood pressure <125 mm Hg at week 4”
> “Change in 24-hour average systolic blood pressure from baseline to week 4 by obesity status”
> “Change in 24-hour average systolic blood pressure from baseline to week 4 by number of BP medications in standardized regimen”
> “Change in office systolic blood pressure from baseline to week 12 among participants escalated to 100 mg daily”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.6.1-9"></a>

###### Key secondary end point defined in the publication abstract

> “A key secondary end point was the change in 24-hour average systolic blood pressure from baseline to week 4, assessed as the placebo-adjusted change in the combined lorundrostat groups.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.6.1-10"></a>

###### Registered secondary outcome measures in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Change from baseline in 24-hour average ABPM SBP at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Baseline to Week 4” |
| “Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “at Week 4” |
| “Change from baseline in 24-hour average ABPM SBP at Week 4 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Baseline to Week 4” |
| “Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)” | “Baseline to Week 12” |
| “Change from baseline in 24-hour average ABPM SBP at Week 4, by number of AHT medications in the standardized AHT regimen (2 and 3) in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Baseline to Week 4” |
| “Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 12 in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo” | “Baseline to Week 12” |
| “Change from baseline in 24-hour average ABPM SBP at Week 12 by obesity status in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo” | “Baseline to Week 12” |
| “Change from baseline in daytime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo” | “Baseline to Week 4 and Week 12” |
| “Change from baseline in AOBP SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo” | “Baseline to Week 4 and Week 12” |
| “Change from baseline in nighttime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo” | “Baseline to Week 4 and Week 12” |
| “Change from baseline in 24-hour average ABPM SBP at Week 12, in subjects randomized to lorundrostat (pooled dosages) compared to subjects randomized to placebo” | “Baseline to Week 12” |

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 285”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.7.1-2"></a>

###### Participants randomized and analyzed for efficacy in the trial presentation

> “285 randomized”
> “94 included in the efficacy analysis”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants in the primary and key secondary analyses stated by the company

> “50 to 100mg (n=94)”
> “50 mg (n=188, at Week 4)”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.7.1-4"></a>

###### Planned sample size and statistical power

No evidence found.

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Comparisons for the primary and key secondary end points in the publication abstract

> “assessed as the least-squares mean difference from placebo (the placebo-adjusted change) in each lorundrostat group.”
> “assessed as the placebo-adjusted change in the combined lorundrostat groups.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.7.2-2"></a>

###### Control of multiplicity for the key secondary end points

> “Controlled for multiplicity with a graphical testing approach”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Within-participant analysis for participants escalated to 100 mg

> “Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)”

Source: [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)

<a id="topic-3.1.2.7.2-4"></a>

###### Hyperkalemia confirmed by repeat testing in the safety analysis

> “The per-protocol procedure for validation of suspected factitious hyperkalemia specified a repeat potassium measurement within 72 hours while still taking study medication to ascertain the true incidence of hyperkalemia.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

> “Confirmed via per protocol repeat testing”
> “Spurious values (including suspected hemolysis) and values obtained following double-blind treatment period are excluded”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Screening, run-in, and randomization in the trial presentation

> “2617 patients assessed for eligibility”
> “1691 ineligible”
> “926 enrolled & started standardized regimen”
> “641 ineligible”
> “53% due to ABPM”
> “285 randomized”
> “94 included in the efficacy analysis”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.1-2"></a>

###### Randomization by treatment group in the publication abstract

> “A total of 285 participants underwent randomization; 94 were assigned to the stable-dose group, 96 to the dose-adjustment group, and 95 to the placebo group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.8.1-3"></a>

###### Participants escalated to 100 mg

> “Change in office systolic blood pressure from baseline to week 12 in participants escalated to 100 mg (n=19)”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.1-4"></a>

###### Discontinuation stated by the company

> “Lorundrostat demonstrated a favorable safety and tolerability profile in the Advance-HTN trial, with modest changes in potassium, sodium and eGFR, and a low discontinuation rate.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Participant characteristics by treatment group in the trial presentation

| Characteristic | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
| --- | --- | --- | --- |
| Age (years) | “59” | “61” | “61” |
| Women (%) | “35%” | “40%” | “44%” |
| Black or African-American (%) | “46%” | “53%” | “58%” |
| BMI (kg/m2) | “32” | “31” | “32” |
| eGFR (randomization) | “74” | “77” | “76” |
| Office BP (screening) | “155/91” | “153/88” | “152/89” |
| 24-hour ABPM (randomization) | “141/87” | “141/86” | “141/87” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### Age and race in the publication abstract

> “The mean age was 60 years, and 150 participants (53%) were Black.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.8.2-3"></a>

###### Obesity, sex, and race stated by the company

> “Key characteristics of participants enrolled in the Advance-HTN trial include: approximately 66% had a BMI greater than or equal to 30kg/m2, approximately 40% were women, and approximately 53% were Black or African American.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary end point: change in 24-hour average systolic blood pressure at week 12

> “After 12 weeks, the least-squares mean change in 24-hour average systolic blood pressure was -15.4 mm Hg in the stable-dose group, -13.9 mm Hg in the dose-adjustment group, and -7.4 mm Hg in the placebo group.”
> “The placebo-adjusted change in blood pressure was -7.9 mm Hg (97.5% confidence interval [CI], -13.3 to -2.6) in the stable-dose group and -6.5 mm Hg (97.5% CI, -11.8 to -1.2) in the dose-adjustment group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary end point: placebo-adjusted changes with P values in the trial presentation

> “Placebo-adjusted: -7.9 (-13.3 to -2.6) P = 0.001”
> “Placebo-adjusted: -6.5 (-11.8 to -1.2) P = 0.006”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-3"></a>

###### Key secondary end point: change in 24-hour average systolic blood pressure at week 4, combined lorundrostat groups

> “The placebo-adjusted change in 24-hour average systolic blood pressure from baseline to week 4 in the combined lorundrostat groups was -5.3 mm Hg (95% CI, -8.4 to -2.3).”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

> “-11.5 mmHg absolute change, -5.3 mmHg placebo-adjusted change (p<0.001)”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

| Group | Least-squares mean change at week 4 (mm Hg) |
| --- | --- |
| Placebo | “-6.2” |
| Lorundrostat 50 mg (all) | “-11.5” |
| Placebo-adjusted difference | “Placebo-adjusted: -5.3 (-8.4 to -2.3) P < 0.001” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-4"></a>

###### Key secondary end point: 24-hour average systolic blood pressure below 125 mm Hg at week 4

| Group | Proportion with 24-hour average SBP <125 mm Hg at week 4 |
| --- | --- |
| Placebo | “18%” |
| Lorundrostat 50 mg (all) | “41%” |
| Odds ratio (95% CI) | “3.3 (1.4 to 7.8) P < 0.001” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

> “41% compared to 18% on placebo (p<0.001)”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.8.3-5"></a>

###### Key secondary end point: change at week 4 by number of background medications

| Background medications | Placebo n | Placebo change (mm Hg) | Lorundrostat n | Lorundrostat change (mm Hg) | Placebo-adjusted difference |
| --- | --- | --- | --- | --- | --- |
| 2 | “n = 60” | “-5.1” | “n = 117” | “-11.2” | “-6.1 (-10.8 to -1.4) P = 0.001” |
| 3 | “n = 34” | “-7.2” | “n = 71” | “-11.8” | “-4.6 (-10.6 to 1.5) P = 0.060” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-6"></a>

###### Key secondary end point: office systolic blood pressure at week 12 in participants escalated to 100 mg

> “Change in office systolic blood pressure from baseline to week 12 in participants escalated to 100 mg (n=19)”
> “-17.5 mm Hg (-30.3 to -4.7) P < 0.001”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-7"></a>

###### Key secondary end point: relationship of body mass index to blood pressure reduction at week 4

> “Relationship of BMI to blood pressure reduction at 4 weeks”
> “No clear relationship”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-8"></a>

###### Dose escalation compared with the stable 50 mg dose

> “A dose escalation strategy from 50 to 100 mg did not lower blood pressure more than 50 mg and was associated with numerically more adverse events”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.3-9"></a>

###### Consistency across subgroups stated by the company

> “Lorundrostat worked equally well in those taking two baseline medications and those taking three or more, and in both men and women as well as in white and black patients.”

Source: [Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal)

<a id="topic-3.1.2.8.3-10"></a>

###### Conclusion of the publication abstract

> “Lorundrostat was associated with greater reductions in 24-hour average blood pressure than placebo in participants with uncontrolled and treatment-resistant hypertension.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Adverse events by treatment group in the trial presentation

| Adverse event | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
| --- | --- | --- | --- |
| Any serious AE | “2%” | “6%” | “8%” |
| Any study-drug related serious AE | “0” | “2%” | “1%” |
| Hypotension | “3%” | “9%” | “8%” |
| Hyponatremia | “6%” | “9%” | “11%” |
| Hyperkalemia (>6.0 mmol/L), single value | “0” | “5%” | “7%” |
| Hyperkalemia (>6.0 mmol/L), confirmed via per protocol repeat testing | “0” | “2%” | “3%” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

<a id="topic-3.1.2.8.5-2"></a>

###### Serious adverse events stated by the company

> “In the Advance-HTN trial, there were six participants (6.4%) and eight participants (8.4%) with treatment-emergent SAEs in the lorundrostat 50 mg and lorundrostat 50 to 100 mg arms, respectively, compared to two participants (2.1%) in the placebo arm. Treatment-related SAEs occurred in 2%, 1%, and 0% of participants in the lorundrostat 50 mg, lorundrostat 50 to 100 mg, and placebo arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-3.1.2.8.5-3"></a>

###### Hyperkalemia above 6.0 mmol per liter

> “A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 5.3% and 7.4% in the 50 mg and 50 to 100 mg arms, respectively.”
> “After exclusion of the spurious results, the values for confirmed hyperkalemia were 2.1% and 3.2%, respectively.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="topic-3.1.2.8.5-4"></a>

###### Hyperkalemia in Advance-HTN compared with Launch-HTN

> “The incidence of hyperkalemia (serum potassium above 6.0 mmol/L) in the 50 mg and 50mg to 100mg arms, respectively, was 1.1% and 1.5% in the Launch-HTN trial and 5.3% and 7.4% in the Advance-HTN trial.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.2.8.5-5"></a>

###### Serum electrolytes and cortisol stated by the company

> “The anticipated on-target effects on serum electrolytes, increased serum potassium and reduced serum sodium were modest and rapidly reversible upon discontinuation of lorundrostat. Suppression of cortisol production was not observed and there was a very low incidence of drug-related serious adverse events (SAEs) resulting in discontinuation or dose-adjustment of study medication.”

Source: [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

Advance-HTN was a 12-week phase 2 trial (the presentation calls it a “Phase 2b trial”) in 285 randomized participants at sites in the United States only (104 locations in the registry record; 103 sites in the presentation). Every participant was switched to a standardized regimen of a diuretic, olmesartan, and, for those previously on 3 to 5 drugs, amlodipine, so the results describe lorundrostat added to that regimen and may differ from its effect on top of usual background therapy; the presenters list the need for “additional data using office blood pressure on top of usual care” from Launch-HTN as a limitation. Of 926 participants who started the standardized regimen, 641 were ineligible for randomization (53% because of the ambulatory blood pressure criterion), which selects a population with confirmed uncontrolled hypertension on a standardized regimen.

The 50 to 100 mg dose-adjustment strategy produced a smaller placebo-adjusted reduction at week 12 (-6.5 mm Hg) than the stable 50 mg dose (-7.9 mm Hg), and 19 participants were escalated to 100 mg, so the trial gives limited information on the 100 mg dose. The week 4 subgroup on 3 background medications (71 lorundrostat and 34 placebo participants) had a placebo-adjusted difference of -4.6 mm Hg with a confidence interval that crossed zero (P = 0.060). The placebo group had a 24-hour systolic reduction of 7.4 mm Hg at week 12.

Single-value potassium above 6.0 mmol/L occurred in 5.3% and 7.4% of the two lorundrostat groups (2.1% and 3.2% after confirmation by repeat testing). The trial was “Not head-to-head with other classes of antihypertensive medications” and “Not a cardiovascular or kidney outcome trial”. As of November 2026 no posted results were located in the registry record, and participant disposition after randomization, discontinuations for adverse events, mean changes in potassium, sodium, and eGFR, and daytime, nighttime, and office blood pressure results by arm are not reported in the publication abstract, the presentation, the registry record, or the company releases.

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf); [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/); [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608); [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from); [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.2.9-2"></a>

###### Limitations stated in the trial presentation

> “Phase 2b trial, additional data using office blood pressure on top of usual care is anticipated from phase 3 trial (Launch-HTN)”
> “Not head-to-head with other classes of antihypertensive medications”
> “Not a cardiovascular or kidney outcome trial”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

Additional sources: [Burgos et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40802954/); [Pollock (2025)](https://pubmed.ncbi.nlm.nih.gov/40802955/)

<a id="heading-3.1.3"></a>

#### 3.1.3 Transform-HTN

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypertension”
> “An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.1-2"></a>

###### Purpose stated by the sponsor

> “Transform-HTN (NCT05968430) is a global open-label extension trial designed to assess the safety, efficacy and tolerability of lorundrostat in participants with hypertension, and includes participants who completed one of three eligible parent studies (Advance-HTN, Launch-HTN or Explore-CKD).”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “Transform-HTN is an open-label extension trial allowing participants to continue to receive lorundrostat and for us to obtain ongoing long-term efficacy and safety data.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “Lorundrostat continues to be evaluated in the ongoing Transform-HTN open-label extension study, which is assessing long-term safety and durability of response.”

Source: [Mineralys Therapeutics press release, ASN Kidney Week 2025 (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/85/data-for-lorundrostat-in-chronic-kidney-disease-and)

<a id="topic-3.1.3.1-3"></a>

###### Role of the trial in the new drug application

> “The Company’s ongoing open-label extension trial, which supported the NDA submission, enables participants to continue to receive lorundrostat and allows the Company to gather additional long-term safety and efficacy data.”

Source: [Mineralys Therapeutics first quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/100/mineralys-therapeutics-reports-first-quarter-2026-financial)

<a id="topic-3.1.3.1-4"></a>

###### Scope of the AHA Scientific Sessions 2026 presentation

> “Transform-HTN is an open-label extension trial of lorundrostat for participants enrolled in 1 of 3 parent studies, including Launch-HTN”
> “This presentation focuses on long-term efficacy and safety of lorundrostat for participants in the lorundrostat arms of the Launch-HTN trial who enrolled in the Transform-HTN OLE trial”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-07-14”
> “Primary Completion (Actual) 2025-12-30”
> “Study Completion (Estimated) 2027-05”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-2"></a>

###### Registered locations

> “This study has 177 locations”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-3"></a>

###### Other study identifiers

> “MLS-101-901”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-4"></a>

###### Certification for delayed results submission

> “Certification/Extension First Submitted 2026-07-15”
> “Certification/Extension First Posted 2026-02-17”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.2-5"></a>

###### Presentation of results

> “The results were presented in a late-breaking oral session at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, IL, on Sunday, November 8, 2026, at 3:35 p.m. CT.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “today announced that new long-term efficacy and safety data from the Company’s ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.”

Source: [Mineralys Therapeutics press release, Transform-HTN late-breaker selection (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/116/mineralys-therapeutics-transform-htn-open-label)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 3” |
| Enrollment | “1076” |

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.3-2"></a>

###### Open-label treatment period, safety follow-up, and optional continuation

> “This study consists of an open label treatment period of 52 weeks followed by a 2-week safety follow-up period.”
> “A Randomized Treatment Withdrawal (RTW) substudy will be performed in a subset of subjects meeting eligibility criteria.”
> “Subjects who complete the open label treatment period will be invited to consent to an optional continuation period where they may remain on study until marketing authorization or early termination of the trial by the sponsor.”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.3-3"></a>

###### Double-blind randomized treatment withdrawal substudy

> “Eligible subjects participating in the RTW will receive double-blind treatment with matching placebo. Upon completion, subjects will return to open-label treatment”
> “lorundrostat or placebo once daily for 4 weeks starting at week 12, in the double-blind randomized treatment withdrawal substudy”
> “Optional for subjects from the MLS-101-301 parent study only”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.3-4"></a>

###### Timeline relative to the Launch-HTN double-blind period

> “Participants eligible for the RTW sub-study had to have a reduction of ≥5 mmHg in office SBP from Launch-HTN baseline at Week 24.”
> “Analysis conducted at Week 48.”
> “Transform-HTN comprises a 52-week treatment period following the 12-week double-blind period in Launch-HTN (overall treatment duration 64 weeks).”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Of the 808 participants from Launch-HTN's lorundrostat treatment arms, 632 participants were eligible and enrolled in Transform-HTN. These participants received an additional 36 weeks of lorundrostat while continuing their existing antihypertensive medications.”
> “The efficacy analysis (n=504) excluded participants randomized to placebo in a four-week randomized treatment withdrawal sub-study between Weeks 24 and 28.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.3-5"></a>

###### Option to enroll at the end of Launch-HTN

> “Upon completion, participants had the option to enroll in an open-label extension trial of lorundrostat or participate in a 2-week safety follow-up.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “At least 18 years of age at the time of signing the informed consent form (ICF)”
> “Completed the EoT or EoS Visit (as applicable) in a lorundrostat study with the option of transitioning to the OLE study, in accordance with the parent study protocol”
> “Fertile male subjects and female subjects of childbearing potential, and their partners, must agree to use an acceptable method of contraception from study entry to 28 days after the last dose of study drug”
> “Willing and able to comply with the study instructions and attend all scheduled study visits”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant, plan to become pregnant, or are breast-feeding”
> “Use, or anticipated use during the course of the study, of a prohibited medication as listed in Section 6.7.1 of the protocol”
> “In the opinion of the Investigator, any condition that will preclude participation in the study”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.4-3"></a>

###### Additional criteria for the randomized treatment withdrawal substudy

> “Written informed consent to participate in the RTW substudy signed by the participant, obtained before any RTW study-related assessment is performed”
> “Non-compliance with study medication(s) (defined as taking <75% or >125% of the study drug provided) during the first 12 weeks of MLS-101-901”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

> “Participants eligible for the RTW sub-study had to have a reduction of ≥5 mmHg in office SBP from Launch-HTN baseline at Week 24.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.4-4"></a>

###### Launch-HTN criteria that defined the presented cohort

> “Office SBP 135-180 mmHg and diastolic BP 65-110 mmHg or isolated office diastolic BP 90-110 mmHg at screening and randomization”
> “2-5 AHTs, including thiazide/thiazide-like diuretic, for ≥1 month pre-screening”
> “eGFR <45 ml/min/1.73 m2”
> “Serum potassium >5.0 mmol/L at screening or >4.8 mmol/L at randomization”
> “Serum sodium <135 mmol/L at screening”
> “Use of epithelial sodium channel inhibitors or MRAs/potassium sparing diuretics”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Registered arms and interventions

> “lorundrostat once daily for 52 weeks depending on when the subject enrolled”
> “lorundrostat or placebo once daily for 4 weeks starting at week 12, in the double-blind randomized treatment withdrawal substudy”
> “lorundrostat once daily from week 52 or until marketing authorization or early termination of the trial by the sponsor”
> “Tablet, administered orally”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.5-2"></a>

###### Open-label starting dose and background antihypertensive drugs

> “These participants received an additional 36 weeks of lorundrostat while continuing their existing antihypertensive medications. The open-label starting lorundrostat dose was 50 mg once daily, or 25 mg if the previously blinded treatment dose was reduced.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

> “Participants who had a permanent dose reduction in Launch-HTN started the OLE at a lorundrostat dose of 25 mg QD.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Change in Automated Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Registered primary outcome measures

> “Change from MLS-101-301 baseline automated office blood pressure (AOBP) systolic blood pressure (SBP) at MLS-101-901 Week 36 in subjects who were enrolled in the lorundrostat arms of MLS-101-301 and were not assigned to the placebo arm of the MLS-101-901 RTW substudy”
> “Change at MLS-101-901 Week 16 (RTW Week 4) from MLS 101-901 Week 12 (RTW substudy baseline) in AOBP SBP in subjects enrolled in RTW”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.6.1-2"></a>

###### Efficacy endpoints in the AHA Scientific Sessions 2026 presentation

> “Primary: Change in office SBP from baseline of Launch-HTN to Week 48”
> “Proportion achieving office SBP <130 mmHg at Week 48”
> “RAAS biomarker changes”
> “Asterisk denotes prespecified efficacy endpoints; other efficacy endpoints were not prespecified.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Eligible participants were enrolled in the open-label extension study, with a primary endpoint of the change in automated office systolic blood pressure.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.6.1-3"></a>

###### Prespecified endpoint: proportion achieving office systolic blood pressure below 130 mmHg

> “Proportion achieving office SBP <130 mmHg at Week 48”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “In Transform-HTN, lorundrostat demonstrated sustained blood pressure reductions for nearly a year, with more than half of participants achieving the guideline-recommended systolic blood pressure target of less than 130 mmHg, an important goal for reducing long-term cardiovascular and kidney risks.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.6.1-4"></a>

###### Safety endpoints and assessment periods

> “TEAEs, AESIs, and confirmed serum potassium elevation”
> “Assessed in the OLE period (Weeks 12-48)”
> “Change in eGFR and serum potassium and sodium”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.6.1-5"></a>

###### Placebo-controlled duration in the parent trial and the purpose of the extension

> “First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “It is no longer ethical to conduct outcome trials that leave one group with untreated hypertension.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.3.6.1-6"></a>

###### Long-term exposure expected for drugs for chronic non-life-threatening conditions

> “Available information suggests that most ADEs first occur, and are most frequent, within the first few months of drug treatment.”
> “Usually 300 to 600 patients should be adequate.”
> “100 patients exposed for a minimum of one-year is considered to be acceptable to include as part of the safety data base.”
> “The data should come from prospective studies appropriately designed to provide at least one year exposure at dosage levels intended for clinical use.”

Source: [FDA guidance, ICH E1A extent of population exposure (1995)](https://www.fda.gov/media/71180/download)

<a id="topic-3.1.3.6.1-7"></a>

###### Randomized withdrawal as a test of maintained effect in approved add-on products

> “The key secondary endpoint was change in seated office systolic blood pressure for BAXFENDY 2 mg compared with placebo from the start (Week 24) to the end (Week 32) of the randomized withdrawal double-blind period of the trial.”
> “Maintenance of the blood pressure lowering effect of BAXFENDY was demonstrated in the double-blind randomized-withdrawal part of the trial.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

> “The persistence of the BP-lowering effect of TRYVIO was demonstrated in part 3 of the trial, in which patients on aprocitentan were re-randomized to placebo or 25 mg aprocitentan following a period during which all patients were treated with 25 mg.”

Source: [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)

<a id="topic-3.1.3.6.1-8"></a>

###### Blood pressure reduction as the basis of cardiovascular benefit

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.3.6.1-9"></a>

###### Unattended automated office measurement in the parent trial

> “After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.”
> “Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Enrollment across all parent studies

> “Enrollment (Actual) 1076”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.7.1-2"></a>

###### Launch-HTN cohort enrolled and analyzed

> “Of 808 patients who received ≥1 dose of lorundrostat in Launch-HTN, 632 (78%) enrolled in the OLE”
> “Efficacy analyses include participants assigned to lorundrostat arms in Launch-HTN who received ≥1 dose of lorundrostat in the OLE and were not assigned to placebo in the RTW (n=504)”
> “Safety analyses include participants assigned to lorundrostat arms in Launch-HTN who received ≥1 dose of lorundrostat in the OLE (n=632)”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.7.1-3"></a>

###### Planned sample size

No evidence found.

<a id="topic-3.1.3.7.1-4"></a>

###### Number randomized in the randomized treatment withdrawal substudy

No evidence found.

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Efficacy and safety analysis sets

> “The efficacy analysis (n=504) excluded participants randomized to placebo in a four-week randomized treatment withdrawal sub-study between Weeks 24 and 28. The safety analysis (n=632) included participants receiving at least one dose of lorundrostat in the open-label extension.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.7.2-2"></a>

###### Population for the registered primary outcome

> “Change from MLS-101-301 baseline automated office blood pressure (AOBP) systolic blood pressure (SBP) at MLS-101-901 Week 36 in subjects who were enrolled in the lorundrostat arms of MLS-101-301 and were not assigned to the placebo arm of the MLS-101-901 RTW substudy”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.7.2-3"></a>

###### Estimand and handling of missing data

> “The LS mean estimate is based on 1,000 imputed datasets using a treatment policy approach.”
> “Data for missing observations at Week 48 were imputed using a shift factor based on change in SBP at Week 12 in the subjects who were randomized to placebo during the double-blind phase.”
> “Data in the figure are observed SBP.”
> “Baseline to Week 12 data for lorundrostat include participants in the 50 mg and 50-100 mg lorundrostat groups of Launch-HTN who entered the OLE.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.7.2-4"></a>

###### Population for the duration of treatment and the eGFR equation

> “Analysis includes participants assigned to double-blind treatment in the 4-week RTW.”
> “eGFR based on CKD-EPI 2021 equation.”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Enrollment, completion, and duration of treatment in the Launch-HTN cohort

> “Of 808 patients who received ≥1 dose of lorundrostat in Launch-HTN, 632 (78%) enrolled in the OLE”
> “549/632 (87%) completed treatment at Week 48”
> “583/632 (92%) completed 48 weeks of follow-up”
> “The median (IQR) duration of treatment was 47.9 weeks (46.7, 48.4)”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Of the 632 participants, 583 (92%) completed 48 weeks of follow-up.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.1-2"></a>

###### Participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline characteristics of the Launch-HTN cohort (safety population)

| Characteristic | Lorundrostat (N=632) |
| --- | --- |
| Age, mean ±SD, years | “61.2 ± 10.5” |
| Female, n (%) | “292 (46.2)” |
| Black or African American, n (%) | “155 (24.5)” |
| Hispanic or Latino, n (%) | “248 (39.2)” |
| BMI ≥30 kg/m2, n (%) | “395 (62.5)” |
| eGFR, mean ±SD, mL/min/1.73 m2 | “92.7 ± 17.4” |
| Office SBP, mean ±SD, mmHg | “148.5 ± 11.9” |
| 2 antihypertensive drugs, n (%) | “262 (41.5)” |
| 3 or more antihypertensive drugs, n (%) | “370 (58.5)” |
| Thiazide or thiazide-like diuretic, n (%) | “601 (95.1)” |
| ACE inhibitor or ARB, n (%) | “546 (86.4)” |
| Calcium channel blocker, n (%) | “295 (46.7)” |
| Beta blockers, n (%) | “209 (33.1)” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.2-2"></a>

###### Baseline office systolic blood pressure of the efficacy population

> “Baseline mean office SBP: 147.9 mmHg”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.2-3"></a>

###### Demographics stated by the sponsor

> “Participants had a mean age of 61 years; 46% were women, 25% were Black or African American and 39% were Hispanic or Latino. Nearly two-thirds (63%) had a BMI of 30 kg/m² or higher; 41% were taking two antihypertensive medications at baseline, while 59% were taking three or more.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint: change in office systolic blood pressure from Launch-HTN baseline to week 48

> “LS mean change from baseline at week 48: -17.8 mmHg (95% CI: -19.6, -16.0); P<0.0001”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “In this open-label extension trial, lorundrostat demonstrated a clinically meaningful 17.8 mmHg absolute reduction in AOSBP from the Launch-HTN baseline through 48 weeks (p<0.0001), supporting sustained blood pressure control.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.3-2"></a>

###### Proportion with office systolic blood pressure below 130 mmHg at week 48

| Group | Participants with office SBP <130 mmHg at week 48 |
| --- | --- |
| Overall | “56.0%” |
| 2 antihypertensive drugs (uncontrolled hypertension) | “55.2%” |
| 3 or more antihypertensive drugs (resistant hypertension) | “56.5%” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “More than half of participants achieved systolic blood pressure below 130 mmHg at the end of the analysis period. Results were similar among participants taking two background antihypertensive medications and those taking three or more.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.3-3"></a>

###### Renin-angiotensin-aldosterone system biomarkers at week 48 (not prespecified)

| Biomarker | Percent change in geometric mean from baseline at week 48 |
| --- | --- |
| Serum aldosterone | “-54.8%” |
| Plasma renin activity | “+123.9%” |
| Aldosterone-renin ratio | “-79.8%” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### Randomized treatment withdrawal substudy: status

> “Randomized treatment withdrawal substudy completed.”

Source: [Mineralys Therapeutics pipeline](https://mineralystx.com/pipeline/)

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)

<a id="topic-3.1.3.8.3-5"></a>

###### Randomized treatment withdrawal substudy: change in automated office systolic blood pressure from week 12 to week 16

No evidence found.

<a id="topic-3.1.3.8.3-6"></a>

###### Efficacy in participants enrolled from Advance-HTN and Explore-CKD

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Adverse events during the 36-week open-label period

| Participants, n (%) | Lorundrostat (N=632) |
| --- | --- |
| Any treatment-emergent adverse event | “413 (65.3)” |
| Moderate intensity | “141 (22.3)” |
| Severe intensity | “20 (3.2)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Any serious adverse event | “27 (4.3)” |
| Death | “0” |
| Treatment-related serious treatment-emergent adverse event (investigator determined) | “2 (0.3)” |
| Hyperkalemia requiring trial drug modification (adverse event of special interest) | “32 (5.1)” |
| Hyponatremia requiring trial drug modification (adverse event of special interest) | “28 (4.4)” |
| Hypotension with symptoms (adverse event of special interest) | “13 (2.1)” |
| Serum potassium >6.0 mmol/L, confirmed per protocol repeat testing | “16 (2.5)” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.5-2"></a>

###### Definition of adverse events of special interest requiring drug modification

> “Trial drug had to be modified due to the adverse event (dose reduction, interruption, or discontinuation).”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Serious adverse events, discontinuations, and hyperkalemia stated by the sponsor

> “Serious adverse events occurred in 27 participants (4.3%). Investigators considered two of these (0.3%) treatment-related. Thirty-seven participants (5.9%) discontinued the trial drug because of an adverse event, including 10 (1.6%) for hyperkalemia.”
> “Hyperkalemia requiring a trial drug modification (dose reduction, interruption, or discontinuation) occurred in 32 participants (5.1%).”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.5-4"></a>

###### Kidney function and serum potassium over time

> “An early drop in eGFR was observed, as expected, after which eGFR remained stable within each study”
> “Creatinine: enzymatic assay”
> “Creatinine: Jaffe assay”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Consistent with lorundrostat’s mechanism of action, serum potassium increased and eGFR decreased early in treatment; both remained stable through the open-label period to Week 48.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-3.1.3.8.5-5"></a>

###### Overall tolerability conclusion of the presenters

> “Treatment with long-term lorundrostat was well tolerated, with no new clinically relevant safety findings”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Lorundrostat was well tolerated during the 36-week open-label extension, with no new clinically relevant safety findings compared with Launch-HTN.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

Transform-HTN is a phase 3, single-group, open-label extension registered with 1,076 participants from three parent studies (Launch-HTN, Advance-HTN, and Explore-CKD). The only results available as of November 2026 are for the Launch-HTN cohort, presented as congress slides and a company press release on November 8, 2026; no peer-reviewed publication and no posted registry results were located, and the record lists a certification or extension request for results submission first submitted on July 15, 2026. Of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled, so the cohort is limited to participants who completed the parent trial and chose to continue, which may favor participants who tolerated and responded to treatment. The primary endpoint is a within-group change from the Launch-HTN baseline, which includes the 12-week double-blind period; after the 12-week double-blind period there was no concurrent control group except during the 4-week withdrawal substudy, and in Launch-HTN the placebo group's automated office systolic blood pressure fell by 7.9 mm Hg at week 6, so the 17.8 mmHg change at week 48 cannot be attributed entirely to lorundrostat. The efficacy analysis (504 participants) excluded participants randomized to placebo in the withdrawal substudy, whereas the safety analysis included all 632; missing week 48 values were imputed with a shift factor based on the parent trial's placebo group. The randomized treatment withdrawal substudy, the only randomized comparison in the trial, is a registered primary outcome (change in automated office systolic blood pressure from extension week 12 to week 16) and is listed as completed, but neither its sample size nor its results were located in any public document. Only the office systolic blood pressure change and the proportion below 130 mmHg were prespecified; the biomarker results were not. Serum creatinine was measured by an enzymatic assay in Launch-HTN and a Jaffe assay in the extension, which limits comparison of eGFR across the two periods. No quality-of-life or patient-reported outcome was reported, and no results were located for participants who entered from Advance-HTN or Explore-CKD.

Source: [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430); [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf); [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from); [Mineralys Therapeutics pipeline](https://mineralystx.com/pipeline/); [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.3.9-2"></a>

###### Interpretive limits of uncontrolled long-term studies

> “A study that has no concurrent control group makes it more difficult to assess the causality relationship between adverse events observed and the test drug.”

Source: [FDA guidance, ICH E1A extent of population exposure (1995)](https://www.fda.gov/media/71180/download)

<a id="heading-3.1.4"></a>

#### 3.1.4 Target-HTN

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Primary objective: safety, efficacy, and dose selection

> “To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials.”
> “The Trial on the Safety and Efficacy of MLS-101 (Lorundrostat) in Patients With Uncontrolled Hypertension (Target-HTN) was designed to examine the safety and efficacy of lorundrostat at 5 different doses in participants with uncontrolled hypertension, with a specific aim of BP reduction among participants with obesity or suppressed renin.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.1-2"></a>

###### Registered purpose of the study

> “A randomized, double-blind, placebo-controlled, dose-ranging, Phase II study to evaluate the safety, efficacy, and tolerability of MLS-101 in Subjects With Uncontrolled Hypertension”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.1-3"></a>

###### Company description of the trial objective

> “The trial was designed to evaluate the safety, efficacy, tolerability and dose response of orally administered lorundrostat for the treatment of uHTN and rHTN when used as add-on therapy to stable background treatment of two or more antihypertensive agents in 200 male and female subjects 18 years of age or older.”

Source: [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Sites in the United States

> “Target-HTN was a multicenter, prospective, randomized, placebo-controlled, dose-ranging clinical trial performed at 43 sites within the United States.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.2-2"></a>

###### Registered locations and study dates

> “This study has 44 locations”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2021-07-01” |
| Primary completion (actual) | “2022-09-07” |
| Study completion (actual) | “2022-10-07” |
| Other study ID number | “MLS-101-201” |
| Sponsor | “Mineralys Therapeutics Inc.” |

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.2-3"></a>

###### Enrollment and follow-up period

> “Between July 2021 and June 2022, 200 participants were randomized, with final follow-up in September 2022.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.2-4"></a>

###### Ethics approval

> “The institutional review boards at the clinical trial sites approved the study, and all participants provided written informed consent.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized, placebo-controlled, dose-ranging design

> “Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications.”
> “In this multicenter, prospective, randomized, placebo-controlled, dose-ranging, double-blind clinical trial among adults with uncontrolled hypertension”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-2"></a>

###### Registered design details

| Field | Quoted record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.3-3"></a>

###### Prescreening, placebo run-in, and 8-week treatment period

> “Participants underwent 2 to 4 weeks of prescreening, a 2-week placebo run-in period to ensure eligibility, and then randomization and treatment for 8 weeks. A final visit was conducted 2 to 4 weeks following completion of the double-blind treatment (eFigure 1 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-4"></a>

###### Single-blind placebo run-in by renin stratum

> “After successful screening, subjects with plasma renin activity (PRA) ≤1ng/mL/h began a single-blind (SB) run-in period of BID oral treatment with placebo (PBO) in Part 1, and subjects with PRA >1ng/mL/h began a SB QD oral treatment with PBO in Part 2, while continuing on stable doses of background AHT medications.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.3-5"></a>

###### Two cohorts defined by plasma renin activity

> “An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-6"></a>

###### Interim analyses and discontinuation of the two lowest doses

> “An independent data and safety monitoring board performed an interim analysis in January 2022, and randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.”
> “An additional interim analysis was performed following the last participant visit from cohort 1 and full enrollment of cohort 2 to guide dose selection in future studies.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-7"></a>

###### Weekly visits and blood pressure measurement schedule

> “Following randomization, all participants’ study visits were conducted at weeks 1 through 8.”
> “Twenty-four-hour ambulatory BP monitoring was measured at baseline and once again prior to the 8-week visit.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.3-8"></a>

###### Trial oversight and sponsor role

> “The trial protocol was designed by Mineralys Therapeutics.”
> “An independent data monitoring committee oversaw patient safety. Cytel performed the statistical analysis, and the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) independently confirmed the primary end-point analysis.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Uncontrolled blood pressure on 2 or more antihypertensive medications

> “Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.4-2"></a>

###### Renin and aldosterone criteria for each cohort

> “Cohort 1 of the study enrolled participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and serum aldosterone level of 1.0 ng/dL or greater based on morning measurements, while cohort 2 enrolled participants with PRA of greater than 1.0 ng/mL/h.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.4-3"></a>

###### Key exclusion criteria

> “Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.”
> “A systolic AOBP of 175 mm Hg or greater, diastolic BP of 100 mm Hg or greater, or serum potassium level greater than 5.2 mmol/L was exclusionary in cohort 1, whereas exclusion criteria in cohort 2 were a systolic AOBP greater than 160 mm Hg, diastolic BP greater than 100 mm Hg, or serum potassium level greater than 4.8 mmol/L.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.4-4"></a>

###### Registered inclusion and exclusion criteria

> “Background antihypertensive treatment of ≥ 2 drugs”
> “Serum cortisol ≥ 18 mcg/dL”
> “Subjects with body mass index > 40 kg/m2”
> “Subjects who, in the opinion of the investigator, have suspected nonadherence to antihypertensive treatment”
> “Strong CYP3A and CYP3A4 inducers”
> “Subjects who are night-shift workers”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Cohort 1: five lorundrostat regimens or placebo

> “Cohort 1 participants were randomly assigned in a 1:1:1:1:1:1 ratio to placebo or 1 of 5 lorundrostat doses (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.5-2"></a>

###### Cohort 2: lorundrostat 100 mg once daily or placebo

> “In the second cohort, participants were randomized in a 1:6 ratio to placebo or lorundrostat, 100 mg once daily.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.5-3"></a>

###### Oral tablets for 8 weeks

> “MLS-101 tablet(s) by mouth once or twice daily.”
> “Placebo tablet(s) by mouth once or twice daily.”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

> “Participants received 50 mg of lorundrostat once daily, taken orally, for 8 weeks in Part 1 of the study”
> “Participants received 100 mg of lorundrostat once daily, taken orally, for 8 weeks in Part 2 of the study”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.5-4"></a>

###### Add-on to stable background antihypertensive therapy with morning dosing

> “Five active doses of lorundrostat (12.5mg once daily QD, 50mg QD, 100mg QD, 12.5mg twice daily [BID], and 25mg BID) were compared to placebo in hypertensive subjects.”

Source: [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)

> “MLS-101 demonstrating substantial placebo-adjusted reduction in blood pressure for 24 hours with once-daily, morning dosing”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Change in Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint: change in automated office systolic blood pressure at week 8

> “The primary efficacy end point was change in systolic AOBP from baseline to the end of study week 8.”
> “Efficacy assessment with AOBP (average of the last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in a seated position) was measured weekly throughout the study.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.6.1-2"></a>

###### Registered primary outcome measure

> “Change From Baseline in Office-measured Systolic Blood Pressure (SBP) at Study Week 8 Compared to Placebo”
> “A least-square estimate of the mean difference between each dose group and the placebo group is provided for Week 8.”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.6.1-3"></a>

###### Blood pressure reduction as the basis of cardiovascular benefit

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “Systolic pressure may be more important than diastolic pressure, especially in the elderly.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.4.6.1-4"></a>

###### Systolic blood pressure reduction and major cardiovascular events

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.4.6.1-5"></a>

###### Unattended automated office blood pressure measurement

> “AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.”
> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”
> “Because having an observer present when BP readings are obtained may lead to inaccurate values (eg, if the patient or observer is talking), it is preferred to have the patient in a room alone for BP measurements (ie, unattended AOBP).”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="topic-3.1.4.6.1-6"></a>

###### Secondary efficacy endpoints

> “Secondary efficacy end points included changes in diastolic AOBP, 24-hour ambulatory BP monitoring changes, and the proportion of participants achieving an AOBP less than 130/80 mm Hg at week 7 or 8.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.6.1-7"></a>

###### Registered secondary outcome measures

> “Change in 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Mean Systolic Blood Pressure (SBP) and Mean Diastolic Blood Pressure (DBP) From Baseline to End of Treatment (EoT)”
> “Week 8 Change From Baseline in Office-measured Diastolic Blood Pressure (DBP)”
> “Number of Participants With Blood Pressure ≤ 130/80 mmHg at Week 8”
> “Each participant was assessed as a success if the Week 8 value for SBP was ≤130 mmHg and DBP ≤80 mmHg; subjects not meeting both these thresholds were assessed as a failure. Subjects missing an assessment at Week 8 or who received rescue medications were also considered failures.”

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.6.1-8"></a>

###### Safety, pharmacodynamic, and adverse events of special interest endpoints

> “Additional safety and pharmacodynamic biomarker end points included changes in PRA, serum aldosterone, cortisol, potassium, and eGFR during the study. Prespecified adverse events of special interest were incidence of hyperkalemia with dose modification, hypotension with symptoms, and adrenal insufficiency.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.6.1-9"></a>

###### Prespecified exploratory subgroups

> “Prespecified subgroups of interest examined the impact of BMI and concomitant administration of a thiazide-type diuretic on the degree of BP lowering.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Sample size rationale

> “The study was designed to provide information regarding a safe and effective dose of lorundrostat for subsequent efficacy trials.”
> “A sample size of 30 participants per group was estimated to provide the half-width of the 2-sided 90% CI of 3.8 mm Hg with a common standard deviation assumed to be 9 mm Hg.”
> “All analyses of cohort 2 of the study were exploratory in nature, and no formal sample size considerations were undertaken for this cohort.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants screened and randomized

> “From July 2021 through June 2022, a total of 380 patients were screened (n = 307 in cohort 1; n = 73 in cohort 2) and 200 participants underwent randomization (n = 163 in cohort 1; n = 37 in cohort 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.1-3"></a>

###### Registered enrollment

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “200” |

Source: [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)

<a id="topic-3.1.4.7.1-4"></a>

###### Participants randomized and analyzed for the primary endpoint by group

| Group | Randomized (baseline table) | Primary end point analysis (efficacy table) |
| --- | --- | --- |
| Cohort 1, lorundrostat 100 mg once daily | “100 mg once daily (n = 30)” | “100 mg once daily (n = 25)” |
| Cohort 1, lorundrostat 50 mg once daily | “50 mg once daily (n = 28)” | “50 mg once daily (n = 28)” |
| Cohort 1, lorundrostat 25 mg twice daily | “25 mg twice daily (n = 30)” | “25 mg twice daily (n = 28)” |
| Cohort 1, lorundrostat 12.5 mg twice daily | “12.5 mg twice daily (n = 22)” | “12.5 mg twice daily (n = 19)” |
| Cohort 1, lorundrostat 12.5 mg once daily | “12.5 mg once daily (n = 23)” | “12.5 mg once daily (n = 19)” |
| Cohort 1, placebo | “Placebo (n = 30)” | “Placebo (n = 29)” |
| Cohort 2, lorundrostat 100 mg once daily | “Lorundrostat, 100 mg once daily (n = 31)” | “Lorundrostat, 100 mg once daily (n = 31)” |
| Cohort 2, placebo | “Placebo (n = 6)” | “Placebo (n = 6)” |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Full analysis set and safety population

> “Analyses were based on the full analysis set, defined as all randomized participants who received at least 1 dose of study medication. A safety analysis population was defined as all participants who took at least 1 dose of study drug.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-2"></a>

###### Mixed-model repeated-measures primary analysis

> “The primary efficacy analysis was performed using a mixed-model repeated-measures approach with fixed effects of categorical terms for treatment, week, and treatment by week interaction, and baseline systolic AOBP as a fixed continuous covariate.”
> “Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-3"></a>

###### Handling of intercurrent events

> “The statistical analysis plan outlined intercurrent events (ICE) that would result in imputation of week 8 BP. Specifically, if rescue BP medications were initiated, the observed systolic BP at time of rescue medication initiation was imputed. Additionally, if participant withdrawal occurred before completion of the 8-week period for a treatment-related reason or worsening, the baseline systolic BP value was imputed as the week 8 measurement.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-4"></a>

###### Secondary analyses and multiplicity

> “All secondary efficacy end-point analyses are considered supportive, and any inferential statistics are considered descriptive in nature. No adjustment for multiplicity was performed due to the phase 2 exploratory intent of the trial.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.7.2-5"></a>

###### Registered analysis populations and cohort 2 comparison

> “The Baseline Analysis Population consisted of all randomized subjects.”
> “The full analysis set included all randomized subjects who received at least 1 dose of randomized study treatment (lorundrostat or placebo). Subjects were analyzed according to the randomized study treatment group.”
> “Per the study SAP, modelled analysis comparisons for Part 2 were performed for 100 mg QD Part 2 vs 100mg QD Part 1, and not to Placebo - Part 2. Accordingly, while subjects were analyzed, modelled LSmeans for Placebo - Part 2 were not reported.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Registered participant flow by group

| Disposition | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Started | “30” | “22” | “30” | “23” | “28” | “30” | “6” | “31” |
| Completed | “29” | “18” | “28” | “18” | “26” | “27” | “6” | “30” |
| Not completed | “1” | “4” | “2” | “5” | “2” | “3” | “0” | “1” |
| Adverse event | “0” | “0” | “0” | “1” | “0” | “0” | “0” | “0” |
| Lost to follow-up | “0” | “1” | “1” | “2” | “0” | “1” | “0” | “0” |
| Not specified by investigator | “0” | “3” | “0” | “0” | “1” | “0” | “0” | “0” |
| Protocol violation | “1” | “0” | “1” | “1” | “0” | “1” | “0” | “0” |
| Withdrawal by subject | “0” | “0” | “0” | “1” | “1” | “1” | “0” | “1” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.1-2"></a>

###### Lowest-dose groups closed after the interim analysis

> “Following the completion of the planned interim analysis, the two lowest doses in Part 1 (i.e., 12.5 mg QD and 12.5 mg BID) were dropped from the study and no further subjects were enrolled in these treatment arms.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.1-3"></a>

###### Intercurrent events by group

> “In the primary analysis population of cohort 1, participants receiving lorundrostat had ICE as follows: 100 mg once daily: 1 had ICE type 1 (initiation of rescue medication; systolic BP that triggered rescue medication is imputed), 4 had ICE type 3 (withdrawal from treatment for treatment-related reason or worsening; baseline systolic BP is imputed), and 3 had ICE type 4 (withdrawal from treatment for non–treatment-related reasons; mixed-model repeated-measures estimate); 50 mg once daily: 1 had ICE type 1; 25 mg twice daily: 1 had ICE type 3 and 2 had ICE type 4; 12.5 mg twice daily: 1 had ICE type 3; and 12.5 mg once daily: 1 had ICE type 1, 4 had ICE type 3, and 4 had ICE type 4. In the placebo group, 1 had ICE type 1 and 1 had ICE type 4. In the primary analysis population of cohort 2 receiving lorundrostat, 2 had ICE type 1, 2 had ICE type 3, and 1 had ICE type 4.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.1-4"></a>

###### Screening outside the run-in

> “Seven participants were inadvertently screened following prescreening failure and did not participate in run-in.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographics and baseline blood pressure of randomized participants

> “Among randomized participants, the mean age was 65.7 (SD, 10.2) years, 60% were women, 36% were Black or African American, and 48% were of Hispanic or Latino ethnicity. At the time of randomization, 48% of participants had a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of greater than 30 and 40% had type 2 diabetes. Three or more antihypertensive medications were taken by 42% of the study population.”
> “Cohort 1 participants had a mean baseline systolic AOBP of 142.2 (SD, 12.5) mm Hg and a mean diastolic AOBP of 81.5 (SD, 9.7) mm Hg, whereas cohort 2 participants had a mean baseline systolic BP of 139.1 (SD, 8.7) mm Hg and diastolic BP of 79.1 (SD, 9.7) mm Hg.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.2-2"></a>

###### Baseline characteristics by group

| Characteristic | Cohort 1, 100 mg QD (n = 30) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 30) | Cohort 1, 12.5 mg BID (n = 22) | Cohort 1, 12.5 mg QD (n = 23) | Cohort 1, placebo (n = 30) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age, mean (SD), y | “68.7 (8.9)” | “64.7 (9.5)” | “64.8 (9.7)” | “68.1 (10.1)” | “65.2 (11.3)” | “62.6 (10.7)” | “66.6 (10.6)” | “62.7 (12.3)” |
| Female, No. (%) | “18 (60.0)” | “15 (53.6)” | “19 (63.3)” | “14 (63.6)” | “12 (52.2)” | “17 (56.7)” | “21 (67.7)” | “4 (66.7)” |
| Black or African American, No. (%) | “15 (50.0)” | “8 (28.6)” | “7 (23.3)” | “7 (31.8)” | “11 (47.8)” | “16 (53.3)” | “6 (19.4)” | “2 (33.3)” |
| White, No. (%) | “14 (46.7)” | “19 (67.9)” | “23 (76.7)” | “15 (68.2)” | “11 (47.8)” | “13 (43.3)” | “25 (80.6)” | “4 (66.7)” |
| Hispanic or Latino ethnicity, No. (%) | “16 (53.3)” | “14 (50.0)” | “17 (56.7)” | “7 (31.8)” | “10 (43.5)” | “12 (40.0)” | “17 (54.8)” | “2 (33.3)” |
| Body mass index, mean (SD) | “30.4 (5.5)” | “32.0 (5.0)” | “30.6 (5.5)” | “32.0 (5.2)” | “30.6 (4.9)” | “31.9 (5.0)” | “30.5 (4.4)” | “32.0 (3.9)” |
| Systolic AOBP at randomization, mean (SD), mm Hg | “142.2 (13.4)” | “140.0 (12.1)” | “142.8 (13.1)” | “142.6 (13.3)” | “142.9 (13.7)” | “142.9 (10.7)” | “139.8 (9.1)” | “135.3 (5.5)” |
| Diastolic AOBP at randomization, mean (SD), mm Hg | “78.5 (10.0)” | “84.7 (7.0)” | “80.1 (9.3)” | “81.6 (9.4)” | “80.3 (12.0)” | “83.8 (9.5)” | “78.6 (10.0)” | “81.5 (7.9)” |
| eGFR, mean (SD), mL/min/1.73 m2 | “77.4 (14.0)” | “77.2 (14.1)” | “80.9 (12.4)” | “81.7 (16.3)” | “77.9 (18.7)” | “81.6 (17.3)” | “79.9 (13.1)” | “83.9 (18.6)” |
| Diabetes, No. (%) | “8 (26.7)” | “8 (28.6)” | “11 (36.7)” | “9 (40.9)” | “11 (47.8)” | “14 (46.7)” | “16 (51.6)” | “2 (33.3)” |
| Heart failure, No. (%) | “1 (3.3)” | “1 (3.6)” | “1 (3.3)” | “1 (4.5)” | “1 (4.3)” | “0” | “0” | “0” |
| 2 background BP medications, No. (%) | “14 (46.7)” | “20 (71.4)” | “14 (46.7)” | “7 (31.8)” | “14 (60.9)” | “17 (56.7)” | “20 (64.5)” | “4 (66.7)” |
| 3 or more background BP medications, No. (%) | “16 (53.3)” | “8 (28.6)” | “16 (53.3)” | “15 (68.2)” | “9 (39.1)” | “13 (43.3)” | “11 (35.5)” | “2 (33.3)” |
| Thiazide-type diuretic use, No. (%) | “17 (56.7)” | “16 (57.1)” | “18 (60.0)” | “13 (59.1)” | “12 (52.2)” | “16 (53.3)” | “19 (61.3)” | “5 (83.3)” |
| ACE inhibitor or ARB use, No. (%) | “23 (76.7)” | “20 (71.4)” | “27 (90.0)” | “17 (77.3)” | “18 (78.3)” | “22 (73.3)” | “30 (96.8)” | “5 (83.3)” |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.2-3"></a>

###### Registered age distribution and region of enrollment

| Characteristic | Total (200 participants) |
| --- | --- |
| Age younger than 65 years | “83” |
| Age 65 to 79 years | “104” |
| Age 80 years or older | “13” |
| Enrolled in the United States | “200” |
| Body mass index, mean (SD), kg/m^2 | “31.1(5.0)” |
| Seated automated office systolic blood pressure, mean (SD), mmHg | “141.6(12.0)” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Primary end point: automated office systolic blood pressure at week 8

| Measure | Cohort 1, 100 mg QD (n = 25) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 28) | Cohort 1, 12.5 mg BID (n = 19) | Cohort 1, 12.5 mg QD (n = 19) | Cohort 1, placebo (n = 29) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline SBP, mean (SD), mm Hg | “143.8 (12.0)” | “141.8 (10.9)” | “140.9 (9.6)” | “144.6 (10.5)” | “147.1 (11.6)” | “142.7 (10.2)” | “140.4 (8.6)” | “132.9 (8.4)” |
| Week 8 SBP, mean (SD), mm Hg | “131.3 (14.1)” | “128.6 (13.7)” | “131.3 (16.6)” | “131.9 (12.9)” | “140.8 (22.0)” | “139.1 (14.2)” | “129.3 (15.4)” | “128.3 (18.9)” |
| Change in SBP, least-squares mean (SE), mm Hg | “−11.9 (2.8)” | “−13.7 (2.7)” | “−11.1 (2.7)” | “−11.3 (3.2)” | “−5.6 (3.2)” | “−4.1 (2.6)” | “−11.4 (2.5)” | Not reported |
| Difference from placebo, least-squares mean (90% CI), mm Hg | “−7.8 (−14.1 to −1.5)” | “−9.6 (−15.8 to −3.4)” | “−7.0 (−13.1 to −0.8)” | “−7.2 (−14.0 to −0.4)” | “−1.5 (−8.3 to 5.3)” | Not applicable | Not reported | Not applicable |
| P value | “.04” | “.01” | “.06” | “.08” | “.71” | Not applicable | Not reported | Not applicable |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-2"></a>

###### Placebo-subtracted change in systolic blood pressure with once-daily doses

> “At week 8, the placebo group demonstrated a change of −4.1 (SE, 2.6) mm Hg in systolic AOBP.”
> “In the once-daily dose cohorts, the placebo-subtracted change in systolic AOBP was −1.5 mm Hg (90% CI, −8.3 to 5.3 mm Hg; P = .71) for 12.5 mg, −9.6 mm Hg (90% CI, −15.8 to −3.4 mm Hg; P = .01) for 50 mg, and −7.8 mm Hg (90% CI, −14.1 to −1.5 mm Hg; P = .04) for 100 mg. The change in BP demonstrated with the twice-daily doses, compared with placebo, showed similar BP reduction.”
> “Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-3"></a>

###### Observed changes in office systolic blood pressure in participants with suppressed renin

> “Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were −10.1 and −13.8 mm Hg, respectively.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-4"></a>

###### Topline placebo-adjusted reductions reported by Mineralys

> “Placebo-adjusted reduction in SBP of 1.4 mmHg (12.5 mg QD, p=NS), 9.7 mmHg (50 mg QD, p=0.010) and 7.9 mmHg (Part 1, 100 mg QD, p=0.037)”
> “Thiazide diuretic as part of background medications placebo-adjusted reduction in SBP of 5.3 mmHg (12.5 mg QD, p=NS), 13.2 mmHg (50 mg QD, p=0.010) and 11.4 mmHg (Part 1, 100 mg QD, p=0.028)”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

<a id="topic-3.1.4.8.3-5"></a>

###### Secondary end point: automated office diastolic blood pressure at week 8

| Measure | Cohort 1, 100 mg QD (n = 25) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 28) | Cohort 1, 12.5 mg BID (n = 19) | Cohort 1, 12.5 mg QD (n = 19) | Cohort 1, placebo (n = 29) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline DBP, mean (SD), mm Hg | “78.9 (9.6)” | “84.9 (6.4)” | “78.9 (8.0)” | “81.6 (7.6)” | “82.4 (10.7)” | “83.4 (8.8)” | “78.1 (7.6)” | “78.3 (7.6)” |
| Week 8 DBP, mean (SD), mm Hg | “73.0 (9.4)” | “76.8 (9.8)” | “75.4 (13.1)” | “75.2 (10.1)” | “81.4 (17.2)” | “81.3 (9.4)” | “72.2 (8.4)” | “76.2 (11.0)” |
| Change in DBP, least-squares mean (SE), mm Hg | “−5.8 (1.8)” | “−7.1 (1.7)” | “−4.1 (1.7)” | “−5.5 (2.0)” | “−3.8 (2.0)” | “−1.6 (1.7)” | “−5.6 (1.4)” | Not reported |
| Difference from placebo, least-squares mean (90% CI), mm Hg | “−4.1 (−8.1 to −0.1)” | “−5.5 (−9.4 to −1.5)” | “−2.5 (−6.4 to 1.4)” | “−3.8 (−8.2 to 0.5)” | “−2.1 (−6.5 to 2.2)” | Not applicable | Not reported | Not applicable |
| P value | “.09” | “.02” | “.30” | “.14” | “.42” | Not applicable | Not reported | Not applicable |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “The 50-mg once-daily dose of lorundrostat decreased diastolic AOBP by 5.5 mm Hg compared with placebo (90% CI, −9.4 to −1.5 mm Hg; P = .02). Other doses did not demonstrate statistically significant lowering of diastolic AOBP compared with placebo.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-6"></a>

###### Secondary end point: ambulatory 24-hour blood pressure

> “Twenty-four-hour ambulatory BP monitoring results including mean overnight and central systolic BP as assessed by pulse-wave velocity are reported in eTables 3 and 4 in Supplement 2.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

| Measure | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants analyzed | “26” | “16” | “26” | “15” | “28” | “24” | “0” | “27” |
| Change in 24-hour mean SBP, least squares mean (SE), mmHg | “-1.01(2.38)” | “-5.78(3.03)” | “-9.05(2.38)” | “-2.51(3.15)” | “-4.86(2.34)” | “-6.34(2.5)” | Not reported | “-1.02(2.64)” |
| Change in 24-hour mean DBP, least squares mean (SE), mmHg | “-0.90(1.46)” | “-5.14(1.85)” | “-6.03(1.45)” | “-2.34(1.91)” | “-3.64(1.40)” | “-6.14(1.51)” | Not reported | “-0.07(1.69)” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.3-7"></a>

###### Secondary end point: blood pressure below 130/80 mm Hg at week 8

> “The proportion of participants with AOBP of less than 130/80 mm Hg at trial conclusion did not statistically differ between treatment groups and placebo (eFigure 3 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

| Measure | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants analyzed | “30” | “22” | “30” | “23” | “28” | “30” | “6” | “31” |
| Participants with blood pressure ≤ 130/80 mmHg at week 8 | “7” | “7” | “13” | “6” | “12” | “9” | “3” | “17” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.3-8"></a>

###### Exploratory subgroups: obesity and thiazide-type diuretic use

> “Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo. With 100 mg once daily of lorundrostat, participants with obesity saw a −12.3 mm Hg (90% CI, −21.6 to −3.1 mm Hg) change in systolic AOBP compared with placebo. Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.”
> “Similarly, participants taking a thiazide-type diuretic randomized to 50 mg or 100 mg once daily of lorundrostat demonstrated changes of −12.9 mm Hg (90% CI, −21.2 to −4.7 mm Hg) and −10.0 mm Hg (90% CI, −21.2 to −1.6 mm Hg) in systolic AOBP compared with placebo. Blood pressure decreases were attenuated among participants not taking a diuretic (eTable 1 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-9"></a>

###### Exploratory cohort 2: participants without suppressed renin

> “Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1. The least-squares mean systolic AOBP difference between the 100-mg once-daily cohorts was 0.74 mm Hg (90% CI, −5.4 to 6.9 mm Hg).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-10"></a>

###### Pharmacodynamic biomarkers: aldosterone, renin activity, and cortisol

> “Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.”
> “In cohort 2, 100 mg daily of lorundrostat decreased mean serum aldosterone by 1.19 (SD, 5.38) ng/dL. Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol (eTable 2 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.3-11"></a>

###### Once-daily compared with twice-daily dosing

> “The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia. Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Deaths, serious adverse events, and overall adverse events

> “No participant deaths occurred during the trial. Three serious adverse events occurred; only 1 was deemed treatment related. A participant randomized to 100 mg once daily of lorundrostat in cohort 2 had worsening of hyponatremia necessitating stopping the drug. A total of 110 participants (55%) experienced any adverse event during the trial (Table 3). Most adverse events were classified as mild by investigators.”
> “One participant was identified with worsening of preexisting coronary artery disease and 1 participant was found to have metastatic cancer in their peritoneum.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-2"></a>

###### Adverse events and serum potassium changes by group

| Measure | Cohort 1, 100 mg QD (n = 30) | Cohort 1, 50 mg QD (n = 28) | Cohort 1, 25 mg BID (n = 30) | Cohort 1, 12.5 mg BID (n = 22) | Cohort 1, 12.5 mg QD (n = 23) | Cohort 1, placebo (n = 30) | Cohort 2, 100 mg QD (n = 31) | Cohort 2, placebo (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Any serious adverse event, No. (%) | “0” | “0” | “0” | “0” | “2 (9)” | “0” | “1 (3)” | “0” |
| Any adverse event, No. (%) | “17 (57)” | “12 (43)” | “20 (67)” | “13 (59)” | “16 (70)” | “12 (40)” | “19 (61)” | “1 (17)” |
| Hypotension, No. (%) | “1 (3)” | “0” | “0” | “1 (5)” | “0” | “0” | “1 (3)” | “0” |
| Change from baseline in serum potassium, mean (SD), mmol/L | “0.29 (0.59)” | “0.25 (0.36)” | “0.34 (0.46)” | “0.32 (0.53)” | “0.31 (0.44)” | “0.03 (0.37)” | “0.21 (0.54)” | “−0.05 (0.28)” |
| Serum potassium 5.6-6.0 mmol/L, No. (%) | “5 (16)” | “1 (4)” | “2 (7)” | “2 (9)” | “3 (13)” | “0” | “2 (6)” | “0” |
| Serum potassium 6.1-6.5 mmol/L, No. (%) | “0” | “0” | “1 (3)” | “1 (5)” | “1 (4)” | “0” | “1 (3)” | “0” |
| Serum potassium >6.5 mmol/L, No. (%) | “1 (3)” | “1 (4)” | “0” | “0” | “0” | “0” | “0” | “0” |

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-3"></a>

###### Hyperkalemia and hypotension

> “Prespecified adverse events of special interest included 3 participants (2%) with hypotension. Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial (Table 3). No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.”
> “Affected individuals were counted once at highest-grade abnormality. Hemolyzed blood samples with serum potassium levels that were not reproducible on repeat testing were not included.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-4"></a>

###### Cortisol and adrenal function

> “No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin (eFigure 4 in Supplement 2).”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-5"></a>

###### Estimated glomerular filtration rate

> “Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures (eTable 2 in Supplement 2).”
> “Examples of more prevalent adverse events included hyperkalemia and decline in estimated glomerular filtration rate.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.8.5-6"></a>

###### Registered serious and other adverse events by group

> “12 weeks; two weeks for Run-in Phase treatment-emergent adverse events (TEAEs) reporting and ten weeks for on-treatment (i.e., post-randomization) TEAE reporting.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

| Adverse event, affected / at risk (%) | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| All-cause mortality | “0/30 (0.00%)” | “0/22 (0.00%)” | “0/30 (0.00%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |
| Serious adverse events, total | “0/30 (0.00%)” | “0/22 (0.00%)” | “0/30 (0.00%)” | “2/23 (8.70%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Other adverse events, total | “7/30 (23.33%)” | “13/22 (59.09%)” | “18/30 (60.00%)” | “16/23 (69.57%)” | “10/28 (35.71%)” | “16/30 (53.33%)” | “1/6 (16.67%)” | “19/31 (61.29%)” |
| Hyperkalemia | “1/30 (3.33%)” | “5/22 (22.73%)” | “9/30 (30.00%)” | “6/23 (26.09%)” | “3/28 (10.71%)” | “8/30 (26.67%)” | “0/6 (0.00%)” | “8/31 (25.81%)” |
| Glomerular filtration rate decreased | “1/30 (3.33%)” | “3/22 (13.64%)” | “0/30 (0.00%)” | “1/23 (4.35%)” | “0/28 (0.00%)” | “5/30 (16.67%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Blood creatinine increased | “0/30 (0.00%)” | “0/22 (0.00%)” | “0/30 (0.00%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “3/30 (10.00%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Urinary tract infection | “0/30 (0.00%)” | “0/22 (0.00%)” | “3/30 (10.00%)” | “1/23 (4.35%)” | “2/28 (7.14%)” | “1/30 (3.33%)” | “0/6 (0.00%)” | “2/31 (6.45%)” |
| Hypotension | “0/30 (0.00%)” | “1/22 (4.55%)” | “0/30 (0.00%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “1/30 (3.33%)” | “0/6 (0.00%)” | “1/31 (3.23%)” |
| Orthostatic hypotension | “0/30 (0.00%)” | “1/22 (4.55%)” | “0/30 (0.00%)” | “2/23 (8.70%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |
| Hypertension | “0/30 (0.00%)” | “0/22 (0.00%)” | “1/30 (3.33%)” | “2/23 (8.70%)” | “2/28 (7.14%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |
| Cortisol decreased | “1/30 (3.33%)” | “2/22 (9.09%)” | “1/30 (3.33%)” | “0/23 (0.00%)” | “0/28 (0.00%)” | “0/30 (0.00%)” | “0/6 (0.00%)” | “0/31 (0.00%)” |

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.8.5-7"></a>

###### Company summary of potassium findings

> “There was an anticipated, modest increase in serum potassium in the two active QD dose cohorts: 0.25 mmol/L in the 50 mg cohort, and 0.35 mmol/L in the 100 mg cohort. Six individuals across the five active dose cohorts experienced an instance of elevated potassium above 6 mmol/L. Per-protocol, study drug administration was reduced, temporarily held or discontinued and consistent with the short half-life of MLS-101; all episodes were rapidly reversible.”
> “An Independent Data Safety Monitoring Board expressed no concerns about the effect of MLS-101 on serum potassium in the Target-HTN trial.”

Source: [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)

> “Adverse events observed were a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection and hypertension with one serious adverse event possibly related to study drug being hyponatremia.”

Source: [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

Target-HTN was a phase 2, dose-ranging trial that randomized 200 participants at sites in the United States to five lorundrostat regimens or placebo for 8 weeks, with no adjustment for multiplicity and with treatment differences reported as 90% confidence intervals. In cohort 1, the primary analysis included 19 to 29 participants per group, and the authors state that “each studied dose had a limited sample size”. Randomization to the 12.5 mg once-daily and 12.5 mg twice-daily groups stopped after the January 2022 interim analysis, and two interim analyses were performed in total. Cohort 1 enrolled only participants with suppressed renin; cohort 2 (37 participants, 6 receiving placebo) was exploratory, with no formal statistical testing against placebo. Sustained hypertension was not confirmed by 24-hour ambulatory monitoring before randomization, which the authors associate with “a prominent white-coat effect” in the 50 mg once-daily group. Participants with an eGFR below 60 mL/min/1.73 m2, or with serum potassium above 5.2 mmol/L (cohort 1) or 4.8 mmol/L (cohort 2), were excluded. The registered results define the proportion at goal as blood pressure of 130/80 mmHg or lower at week 8, while the publication describes it as below 130/80 mm Hg at week 7 or 8. The trial protocol was designed by the sponsor, Mineralys Therapeutics, which also provided input on the manuscript.

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/); [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.9-2"></a>

###### Limitations stated by the authors

> “This trial has limitations. First, multiple dosing regimens were tested for efficacy, and each studied dose had a limited sample size. Second, 24-hour ambulatory BP monitoring was not used to confirm sustained hypertension before randomization, and this resulted in a disproportionate percentage of participants with a prominent white-coat effect in the 50-mg once-daily lorundrostat group. Third, cohort 1 of this trial selected participants with suppressed renin at baseline.”
> “Fourth, 2 interim analyses were performed; multiple interim analyses would not be appropriate in subsequent confirmatory trials.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.9-3"></a>

###### Need for confirmatory studies

> “Among individuals with uncontrolled hypertension, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.9-4"></a>

###### Registered limitations and caveats

> “Following the completion of the planned interim analysis in January 2022, the two lowest doses in Part 1 (i.e., 12.5 mg QD and 12.5 mg BID) were dropped from the study and no further subjects were enrolled in these treatment arms. Accordingly, overall subject numbers in these arms is less than originally planned.”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="topic-3.1.4.9-5"></a>

###### Sponsor role in the protocol and manuscript

> “The trial protocol was designed by Mineralys Therapeutics.”
> “The first author (L.J.L.) wrote the first version of the manuscript and made revisions following input from coauthors and the sponsor.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-3.1.4.9-6"></a>

###### Publication restrictions on investigators

> “There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed”

Source: [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)

<a id="heading-3.1.5"></a>

#### 3.1.5 Explore-CKD

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB).”
> “A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.1-2"></a>

###### Aim stated in the published report

> “The trial’s aim was to evaluate the efficacy and safety of lorundrostat added to an SGLT2i in participants with uncontrolled hypertension, CKD, and persistent albuminuria despite receiving stable treatment with an ACEi or ARB.”
> “Building on this evidence, the present trial was designed to evaluate the efficacy and safety of lorundrostat in participants with uncontrolled hypertension and CKD.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.1-3"></a>

###### Purpose stated by the sponsor

> “The Explore-CKD trial was designed to provide data that augments the antihypertensive profile of lorundrostat by evaluating the efficacy and safety of lorundrostat in subjects with compromised renal function.”

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual)”
> “2023-12-14”
> “Primary Completion (Actual)”
> “2025-02-27”
> “Study Completion (Actual)”
> “2025-04-23”
> “Results First Posted”
> “2026-06-03”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.2-2"></a>

###### Registered locations

> “This study has 44 locations”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.2-3"></a>

###### Sites and enrollment period in the published report

> “Explore-CKD (ClinicalTrials.gov identifier NCT06150924) was a phase 2, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-sequence crossover trial conducted at 42 sites in the United States.”
> “Between December 14, 2023, and April 23, 2025, a total of 378 participants underwent screening, of whom 85 entered the run-in period and 59 were randomized 1:1 to the 2 treatment sequences”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.2-4"></a>

###### Sites stated by the sponsor

> “Explore-CKD randomized 59 participants at 42 sites in the United States.”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

<a id="topic-3.1.5.2-5"></a>

###### Other study identifiers

> “MLS-101-206”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Two-period, two-sequence crossover design

> “Explore-CKD (ClinicalTrials.gov identifier NCT06150924) was a phase 2, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-sequence crossover trial conducted at 42 sites in the United States.”
> “After a screening period of up to 2 weeks, eligible participants entered a 2-week run-in period where SGLT2i-naive participants began trial-provided dapagliflozin 10 mg once daily (Figure 1).”
> “Participants with SBP ≥135–180 mm Hg at the end of run-in period were eligible to be randomized 1:1 to lorundrostat 25 mg once daily–placebo arm or placebo–lorundrostat 25 mg once daily arm in 4-week treatment sequences, with a 4-week washout in between the treatment sequences.”
> “After randomization, clinical visits were conducted at weeks 2, 4, 8, 10, and 12 (the last visit of the treatment period) (Figure 1).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.3-2"></a>

###### Study periods in the ClinicalTrials.gov record

> “The study consists of up to a 2-week Screening period, a 2-week run-in period where subjects will either begin study provided dapagliflozin 10 mg or continue on their regularly prescribed SGLT2i, and two DB 4-week treatment periods separated by a 4-week washout period. Subjects will be randomized (1:1) to two treatment sequences: lorundrostat-placebo (LP) and placebo-lorundrostat (PL).”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.3-3"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “60” |

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.3-4"></a>

###### Blood pressure measurement procedure

> “Unattended AOBP was assessed at each study visit.”
> “Each site was provided with an identical automated oscillometric blood pressure device (WatchBP Office AFIB, Microlife AG), training, and an instruction manual for collecting blood pressure measurements.”
> “After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute interval between each reading; the last 4 measures were used to calculate the average to reduce within-participant variance in measuring blood pressure.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.3-5"></a>

###### Oversight and sponsor role

> “The trial was designed by Mineralys Therapeutics, with contribution from external scientific advisers.”
> “The Explore-CKD trial was funded by Mineralys Therapeutics.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Key inclusion and exclusion criteria in the published report

> “Eligible participants were ≥18 years of age with uncontrolled hypertension (seated automated office SBP [AOSBP] 135–180 mm Hg) and CKD stage 1–3b (eGFR ≥30 ml/min per 1.73 m2 based on creatinine estimation”
> “Participants were required to have received stable treatment with an ACEi or ARB for at least 4 weeks before screening.”
> “Key exclusion criteria were serum potassium >5.0 mmol/l, serum sodium <135 mmol/l, eGFR <30 ml/min per 1.73 m2, and uncontrolled diabetes (glycated hemoglobin >10%).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.4-2"></a>

###### Major inclusion criteria in the ClinicalTrials.gov record

> “At Screening, UACR of 200-5000 mg/g, inclusive, in first morning urine void”
> “At Screening, eGFRs of ≥30 mL/min/1.73 m2”
> “At Screening, AOBP SBP of 135-180 mmHg, inclusive”
> “On a stable treatment with an ACEi or ARB for at least 2 months prior to Screening”
> “At Screening, body mass index (BMI) of >18 kg/m2”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.4-3"></a>

###### Major exclusion criteria in the ClinicalTrials.gov record

> “At Screening, serum potassium >5.0 mmol/L”
> “History of clinically significant hyponatremia within 1 year prior to Screening”
> “Use of epithelial sodium channel (ENaC) inhibitors or Mineralocorticoid receptor antagonist (MRAs), including, but not limited to amiloride, triamterene, spironolactone, eplerenone, finerenone, from 4 weeks prior to the Screening Visit and during study participation. With the exception of MRAs in primary aldosteronism”
> “Medical history of kidney disease related to autoimmune diseases (lupus, anti-neutrophil cytoplasmic antibody [ANCA] vasculitis), multiple myeloma or other known paraproteins, infiltrative diseases of the kidney, obstructive nephropathy, cystic kidney diseases, and renal transplantation”
> “Medical history of advanced liver disease, including cirrhosis”
> “Diabetes mellitus with a glycosylated hemoglobin (HbA1c) >10% (>86 mmol/mol) at Screening”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.4-4"></a>

###### Ages eligible in the ClinicalTrials.gov record

> “18 Years and older”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.4-5"></a>

###### Chronic kidney disease stages described by the sponsor

> “Explore-CKD evaluated the safety and efficacy of 25 mg once daily (QD) lorundrostat in addition to a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of hypertension in participants with Stage 2 to 3b CKD and albuminuria despite receiving stable treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB).”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Lorundrostat 25 mg or placebo once daily on background ACEi or ARB and SGLT2 inhibitor

> “Participants already receiving an SGLT2i could either switch to trial-provided dapagliflozin or continue with their prescribed SGLT2i.”
> “All participants were maintained on background therapy with an ACEi or ARB and an SGLT2i during the trial.”
> “Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.”
> “Participants were reminded about taking their trial medication using a smartphone application (AiCure).”
> “A dose modification to 12.5 mg was allowed for safety reasons on the basis of each participant’s safety data.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.5-2"></a>

###### Treatment sequences in the ClinicalTrials.gov record

> “Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks”
> “Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Change in Automated Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

###### Primary endpoint

> “The primary efficacy end point was the placebo-adjusted change in AOSBP.”
> “Efficacy end points were assessed after completion of each 4-week randomized treatment period (Figure 1).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-2"></a>

###### Registered primary outcome measure

> “Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4”
> “Baseline to Week 4”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.6.1-3"></a>

###### Blood pressure control in chronic kidney disease

> “Adequate blood pressure control in individuals with CKD has been demonstrated to not only slow progression of renal damage but also reduce the risk of cardiovascular disease.”
> “Approximately 76% of people with comorbid CKD and hypertension have uncontrolled blood pressure despite treatment with multiple antihypertensive medications.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-4"></a>

###### Clinical relevance of the systolic blood pressure reduction stated by the investigators

> “Blood pressure improvement of this magnitude is known to be clinically relevant in patients with CKD.”
> “A meta-analysis of 26 randomized clinical trials of antihypertensive therapy in participants with or without CKD demonstrated that each 5-mm Hg reduction in SBP reduced the risk of major cardiovascular events by approximately 18%, with similar results observed for different medication classes and in patients with different eGFR levels.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-5"></a>

###### Blood pressure reduction as the basis of cardiovascular benefit in FDA labeling guidance

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.5.6.1-6"></a>

###### Systolic blood pressure reduction and major cardiovascular events in an individual participant data meta-analysis

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.5.6.1-7"></a>

###### Automated office blood pressure measurement

> “AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.”
> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="topic-3.1.5.6.1-8"></a>

###### Unattended compared with attended automated office blood pressure

> “The unattended systolic BP and diastolic BP were −2.7 (−4.7 to −0.6) and −0.9 (−1.8 to −0.1) mm Hg lower than attended BPs.”

Source: [Deragon et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826897/)

<a id="topic-3.1.5.6.1-9"></a>

###### Exploratory endpoints

> “Exploratory end points included the change in 24-hour urine albumin and protein, automated office diastolic blood pressure, UACR (both spot urine and 24-hour urine), and eGFR.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-10"></a>

###### Rationale for albuminuria as an exploratory endpoint

> “Albuminuria is an independent predictor of kidney damage, and changes in UACR have been proposed as a surrogate end point in trials of CKD progression and end-stage renal disease.”
> “A meta-analysis of clinical trials and observational studies in patients with early-stage kidney disease found that a 30% reduction in UACR sustained over 1–2 years was associated with an approximately 20% lower risk of end-stage renal disease.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-11"></a>

###### Rationale for cystatin C estimated glomerular filtration rate

> “eGFR was estimated using the 2012 cystatin C Chronic Kidney Disease Epidemiology Collaboration equation to assess falsely elevated creatinine levels due to competition between lorundrostat and creatinine for the multidrug and toxin extrusion protein 1 transporter.”
> “eGFR was additionally estimated using the 2021 serum creatinine Chronic Kidney Disease Epidemiology Collaboration equation.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-12"></a>

###### Safety endpoints and adverse events of special interest

> “Safety was assessed throughout the trial as the incidence and severity of adverse events (AEs).”
> “AEs of special interest included modification of study drug dose, including dose reduction, dose hold, or permanent dose discontinuation due to hyperkalemia, hyponatremia, reduction in kidney function, or hypercortisolism (defined as morning serum cortisol >35 μg/dl, confirmed by 24-hour urinary free cortisol).”
> “Other AEs of special interest included symptomatic hypotension, severely elevated blood pressure (AOSBP >180 mm Hg or automated office diastolic blood pressure >110 mm Hg), and discontinuation of the trial drug due to hypocortisolism confirmed by an adrenocorticotropic hormone stimulation test.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Planned sample size and power

> “A sample size of 60 participants randomized in a 1:1 ratio to the 2 sequences (lorundrostat 25 mg once daily–placebo and placebo–lorundrostat 25 mg once daily) had 85% power to detect a placebo-adjusted reduction in AOSBP ≥5.5 mm Hg pooling both treatment periods in a joint longitudinal analysis, assuming 14 mm Hg as an SD of change on the basis of data from completed lorundrostat clinical trials.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.1-2"></a>

###### Participants screened and randomized in the published report

> “Between December 14, 2023, and April 23, 2025, a total of 378 participants underwent screening, of whom 85 entered the run-in period and 59 were randomized 1:1 to the 2 treatment sequences (lorundrostat 25 mg once daily–placebo, n = 30; placebo–lorundrostat 25 mg once daily, n = 29) (Figure 2).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.1-3"></a>

###### Enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual)”
> “60”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.7.1-4"></a>

###### Participants analyzed in the posted results

| Analysis | Placebo | Lorundrostat |
| --- | --- | --- |
| Primary outcome, overall number of participants analyzed | “58” | “58” |
| All-cause mortality, affected / at risk (%) | “0/57 (0.00%)” | “0/58 (0.00%)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Estimand and handling of missing data for the primary endpoint

> “All P values are provided as 2-sided with 95% confidence intervals.”
> “The primary end point followed the treatment policy approach by using all observed efficacy data regardless of possible treatment discontinuation.”
> “Data missing due to intercurrent events were considered not missing at random and were imputed by the jump to reference (placebo) approach. Other missing data were imputed as missing at random.”
> “The primary end point was analyzed on 1000 multiply imputed data sets.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.2-2"></a>

###### Crossover model, sensitivity analysis, and parallel-group analyses

> “The mixed model included 2 baselines (week 0 for treatment period 1 and week 8 for treatment period 2).”
> “A sensitivity analysis was performed using a mixed-effects model, including treatment, period, and sequence as fixed factors, participants as a random factor, and a baseline value (week 0 or week 8) as a covariate.”
> “The analysis of change in spot UACR was performed on log-transformed values using a single common baseline (treatment period 1 week 0) because no spot urine collection occurred at week 8.”
> “To further validate the results, we analyzed differences in AOSBP and 24-hour UACR changes between placebo- and lorundrostat-treated subjects during each treatment period as 2 stand-alone, parallel randomized controlled trials (Supplementary Table S1).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.2-3"></a>

###### Attribution of adverse events to treatment periods

> “AEs reported during the washout period or during the safety follow-up period were assigned to the treatment received in treatment period 1 or treatment period 2, respectively.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.2-4"></a>

###### Adverse event reporting in the posted results

> “Adverse events that occurred during the Washout Period were attributed to treatment administered during Treatment Period 1. Adverse events that occurred during the Safety Follow-up Period were considered TEAEs if they occurred within 14 days of the start of the Safety Follow-up Period and were attributed to administered during Treatment Period 2.”
> “Placebo, pooled across both randomization sequence cohorts”
> “Lorundrostat, pooled across both randomization sequence cohorts”

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### Screening, randomization, and open-label extension enrollment

> “Between December 14, 2023, and April 23, 2025, a total of 378 participants underwent screening, of whom 85 entered the run-in period and 59 were randomized 1:1 to the 2 treatment sequences (lorundrostat 25 mg once daily–placebo, n = 30; placebo–lorundrostat 25 mg once daily, n = 29) (Figure 2).”
> “A majority (54 of 59) of participants enrolled in an ongoing open-label extension (OLE) trial (ClinicalTrials.gov identifier NCT05968430).”
> “Three participants discontinued treatment because of AEs, 2 attributed to lorundrostat treatment (hyperkalemia/acute kidney injury and CKD worsening) and 1 to placebo treatment (retinal detachment).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.1-2"></a>

###### Participant flow in the posted results

| Milestone | Cohort 1 (lorundrostat, then placebo) | Cohort 2 (placebo, then lorundrostat) |
| --- | --- | --- |
| Started | “30” | “29” |
| Completed | “29” | “28” |
| Not completed | “1” | “1” |
| Reason not completed: physician decision | “1” | “1” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographic and disease characteristics in the published report

> “Baseline demographic and disease characteristics were similar between the 2 randomized sequences and are listed in Table 1.”
> “Participants were 69.5% male and 66.1% white, with a mean age of 64.6 years and a mean body mass index of 33.1 kg/m2.”
> “At baseline, the mean AOSBP was 148.9 mm Hg, the automated office diastolic blood pressure was 82.0 mm Hg, the geometric mean spot UACR was 516.8 mg/g, and the mean eGFR (creatinine) was 54.6 ml/min per 1.73 m2.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.2-2"></a>

###### Baseline characteristics table (N = 59)

| Characteristic | Value |
| --- | --- |
| Age, years, mean ± SD | “64.6 ± 10.14” |
| Age 75 years or older, n (%) | “13 (22.0)” |
| Male, n (%) | “41 (69.5)” |
| Female, n (%) | “18 (30.5)” |
| White, n (%) | “39 (66.1)” |
| Black or African American, n (%) | “10 (16.9)” |
| Hispanic or Latino, n (%) | “25 (42.4)” |
| Body mass index, kg/m2, mean ± SD | “33.1 ± 7.10” |
| Seated automated office systolic blood pressure, mm Hg, mean ± SD | “148.9 ± 10.37” |
| Seated automated office diastolic blood pressure, mm Hg, mean ± SD | “82.0 ± 10.49” |
| eGFR (cystatin C), ml/min per 1.73 m2, mean ± SD | “43.0 ± 14.97” |
| eGFR (creatinine), ml/min per 1.73 m2, mean ± SD | “54.6 ± 21.08” |
| UACR (24 hr), mg/g, geometric mean ± SD | “559 ± 2.55” |
| Two or fewer antihypertensive medications, n (%) | “21 (35.6)” |
| Three or more antihypertensive medications, n (%) | “38 (64.4)” |
| β-Blockers, n (%) | “28 (47.5)” |
| Selective calcium-channel blockers with mainly vascular effects, n (%) | “30 (50.8)” |
| Type 2 diabetes mellitus, n (%) | “45 (76.3)” |
| SGLT2i-naive at screening, n (%) | “26 (44.1)” |

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.2-3"></a>

###### Baseline systolic blood pressure by sequence in the posted results

| Group | Seated automated office systolic blood pressure, mmHg, mean (SD) |
| --- | --- |
| Cohort 1 (lorundrostat, then placebo) | “147.008(9.8704)” |
| Cohort 2 (placebo, then lorundrostat) | “150.802(10.6962)” |
| Total | “148.873(10.3731)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Primary endpoint: change in automated office systolic blood pressure at week 4

> “Four weeks of lorundrostat treatment resulted in a statistically significant reduction in AOSBP compared with placebo.”
> “The least squares (LS) mean change from baseline AOSBP was −9.3 mm Hg for lorundrostat and −1.8 mm Hg for placebo (placebo-adjusted change −7.5 mm Hg; 95% confidence interval −12.3 to −2.7 mm Hg; P = 0.0024) (Figure 3a).”
> “The mean baseline AOSBP was reduced from 143.3 ± 12.90 to 134.6 ± 13.99 mm Hg with lorundrostat treatment and from 144.6 ± 14.41 to 142.4 ± 15.5 mm Hg with placebo (Figure 3b).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-2"></a>

###### Period and carryover effects

> “There was no evidence of a period (P = 0.6821) or carryover (P = 0.7384) effect for SBP evaluated using the model described in Lim and In.”
> “The absence of a carryover effect (P = 0.7234) was reconfirmed using a model described in Shen and Luz.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-3"></a>

###### Primary outcome in the posted results

| Measure | Placebo | Lorundrostat |
| --- | --- | --- |
| Least squares mean change from baseline, mmHg | “-1.755” | “-9.253” |
| 90% confidence interval | “(-4.966 to 1.455)” | “(-12.453 to -6.053)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.8.3-4"></a>

###### Automated office diastolic blood pressure

> “Automated office diastolic blood pressure was reduced by 3.9 mm Hg with lorundrostat and 1.4 mm Hg with placebo (LS mean difference −2.6 mm Hg) (Supplementary Figure S2).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-5"></a>

###### Albuminuria and proteinuria

> “All proteinuria indices decreased from baseline by 20.9%–30.5% with lorundrostat treatment.”
> “The placebo-adjusted LS mean percent change in proteinuria for lorundrostat versus placebo was significant for all 3 indices: −25.6% (P = 0.0015) for spot UACR, −26.1% (P < 0.0001) for 24-hour UACR, and −22.1% (P = 0.0002) for 24-hour urine protein-to-creatinine ratio (Figure 4).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-6"></a>

###### Estimated glomerular filtration rate

> “The LS mean decrease in cystatin C–estimated eGFR was 2.74 ml/min per 1.73 m2 with lorundrostat and 0.77 ml/min per 1.73 m2 with placebo, corresponding to a placebo-adjusted decrease of 1.97 ml/min per 1.73 m2 (95% confidence interval −3.83 to −0.11 ml/min per 1.73 m2; P = 0.0380) and a placebo-adjusted percent change of −4.58% (P = 0.0362).”
> “The LS mean decrease in creatinine-estimated eGFR was 8.42 ml/min per 1.73 m2 with lorundrostat and 2.34 ml/min per 1.73 m2 with placebo, corresponding to a placebo-adjusted decrease of 6.09 ml/min per 1.73 m2 (95% confidence interval −8.12 to −4.05 ml/min per 1.73 m2; P < 0.0001) and a placebo-adjusted percent change in creatinine-estimated eGFR of −11.39% (P < 0.0001).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-7"></a>

###### Aldosterone and renin

> “The geometric mean serum aldosterone level decreased by 41.5% during treatment with lorundrostat and increased by 1.8% during placebo treatment. The geometric mean plasma renin activity increased by 75.2% with lorundrostat and 4.2% with placebo. The geometric mean aldosterone-to-renin ratio decreased by 67.2% during treatment with lorundrostat and by 5.8% with placebo.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-8"></a>

###### Topline results table in the sponsor release

| Measure | Placebo | Lorundrostat 25 mg | Placebo-adjusted |
| --- | --- | --- | --- |
| Change in systolic BP (mmHg), primary endpoint | “-1.76” | “-9.25” | “-7.5 (p=0.0024)” |
| Change in spot UACR (mg/g) | “-6.60%” | “-30.51%” | “-25.60% (p=0.0015)” |
| Change in eGFR, cystatin C (mL/min/1.73m2) | “-2.20%” | “-6.78%” | “-4.58% (p=0.0362)” |

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.5.8.3-9"></a>

###### Analysis basis of the topline estimates

> “Per protocol Systolic BP, UACR, and eGFR estimates and p values from Mixed Effects Model for a crossover trial with multiple baselines.”

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Treatment-emergent adverse events

> “Ninety treatment-emergent AEs (TEAEs) were reported by 48 participants (Table 2).”
> “At least 1 TEAE was reported by 29 of 58 participants on lorundrostat (50%) and by 19 of 57 participants during placebo treatment (33%).”
> “TEAEs considered related to treatment occurred in 16 participants while receiving lorundrostat (27.6%) and 8 participants while receiving placebo (14.0%).”
> “Most treatment-related TEAEs were considered mild to moderate in severity, with 2 severe events occurring in 1 participant in the lorundrostat group (1.7%). There were no severe TEAEs with placebo treatment.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-2"></a>

###### Overview of treatment-emergent adverse events, n (%) and number of events

| Event | Placebo (n = 57) | Lorundrostat (n = 58) |
| --- | --- | --- |
| TEAEs | “19 (33.3) [36]” | “29 (50.0) [54]” |
| Treatment-related TEAEs | “8 (14.0) [9]” | “16 (27.6) [24]” |
| Serious adverse events | “0 (0.0) [0]” | “2 (3.4) [4]” |
| Adverse events of special interest | “1 (1.8) [1]” | “10 (17.2) [13]” |
| TEAEs leading to discontinuation of the trial drug | “1 (1.8) [1]” | “2 (3.4) [3]” |
| TEAEs leading to dose modification of the trial drug | “4 (7.0) [4]” | “12 (20.7) [15]” |
| Death | “0 (0.0) [0]” | “0 (0.0) [0]” |

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-3"></a>

###### Most common adverse events

> “The most commonly reported TEAEs during placebo or lorundrostat treatment were hyperkalemia (lorundrostat, n = 9 [15.5%]; placebo, n = 2 [3.5%]), GFR decrease (lorundrostat, n = 6 [10.3%]; placebo, n = 2 [3.5%]), hyponatremia (lorundrostat, n = 3 [5.2%]; placebo, n = 3 [5.3%]), and hypotension (lorundrostat, n = 3 [5.2%]; placebo, n = 2 [3.5%])”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-4"></a>

###### Adverse events of special interest and discontinuations

> “AEs of special interest were experienced by 10 participants with lorundrostat treatment (17.2%) and 1 participant with placebo (1.8%).”
> “Per protocol modification of the study drug dose due to hyperkalemia and reduction in kidney function were the most common AEs of special interest, occurring in 8.6% (n = 5) and 10.3% (n = 6) of participants during lorundrostat treatment, respectively, versus none with placebo.”
> “Three participants discontinued treatment because of AEs, 2 attributed to lorundrostat treatment (hyperkalemia/acute kidney injury and CKD worsening) and 1 to placebo treatment (retinal detachment). There were no deaths reported during the trial (Table 2).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-5"></a>

###### Hyperkalemia

> “Three participants (5.2%) had confirmed serum potassium of >6.0 mmol/l while under lorundrostat treatment (Table 3).”
> “Hyperkalemic events occurred in participants receiving background ACEi/ARB and SGLT2i therapy.”
> “In this trial, increases in serum potassium were managed with lorundrostat dose reduction, temporary dose interruption, and/or standard medical management, including potassium binders.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-6"></a>

###### Participants with at least 1 confirmed elevated potassium value, n (%)

| Prespecified level | Placebo (n = 57) | Lorundrostat (n = 58) |
| --- | --- | --- |
| Level 1: >5.5–6.0 mmol/l | “1 (1.8)” | “4 (6.9)” |
| Level 2: >6.0–6.5 mmol/l | “0 (0.0)” | “2 (3.4)” |
| Level 3: >6.5 mmol/l | “0 (0.0)” | “1 (1.7)” |

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-7"></a>

###### Sodium, kidney function, and cortisol

> “No serum sodium values <125 mmol/l occurred (Supplementary Table S6). Nine participants experienced an eGFR (cystatin C) decrease ≥25%.”
> “There were no eGFR decreases ≥50% (Supplementary Table S7), and no participants had a ≥2-fold elevation in serum creatinine. No clinically meaningful changes in serum cortisol were observed in either treatment sequence.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-8"></a>

###### Serious adverse events in the posted results

| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
| --- | --- | --- |
| Total | “0/57 (0.00%)” | “2/58 (3.45%)” |
| Influenza | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Hyperkalaemia | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Acute kidney injury | “0/57 (0.00%)” | “1/58 (1.72%)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.8.5-9"></a>

###### Other adverse events in the posted results (frequency threshold 2%)

| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
| --- | --- | --- |
| Total | “18/57 (31.58%)” | “29/58 (50.00%)” |
| Glomerular filtration rate decreased | “2/57 (3.51%)” | “6/58 (10.34%)” |
| Hyperkalaemia | “2/57 (3.51%)” | “9/58 (15.52%)” |
| Hyponatraemia | “3/57 (5.26%)” | “3/58 (5.17%)” |
| Hypotension | “2/57 (3.51%)” | “3/58 (5.17%)” |
| Orthostatic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |
| Diastolic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.8.5-10"></a>

###### Discontinuations reported in the topline release

> “During lorundrostat treatment, one subject discontinued treatment due to elevation of potassium associated with reduced eGFR and one subject discontinued treatment due to reduction in eGFR alone.”

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

Explore-CKD was a phase 2, two-period, two-sequence crossover trial with 4-week treatment periods separated by a 4-week washout. The publication reports 59 randomized participants at 42 sites in the United States; the registry lists an enrollment of 60 and 44 locations. One dose, lorundrostat 25 mg once daily, was studied. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure; albuminuria, proteinuria, and eGFR were exploratory endpoints, and no kidney or cardiovascular outcome was assessed. The investigators state that the 4-week treatment period “does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes” and that the findings “will require confirmation in a larger, longer-duration, parallel-arm trial”. Participants with serum potassium above 5.0 mmol/L at screening were excluded, which, with the short treatment duration, the investigators state “could underestimate hyperkalemia risk in routine clinical practice”; hyperkalemia was reported in 9 of 58 participants (15.5%) during lorundrostat treatment and 2 of 57 (3.5%) during placebo. The registry requires stable ACEi or ARB treatment for at least 2 months before screening, and the publication states at least 4 weeks. The trial was designed and funded by Mineralys Therapeutics, three authors are company employees, and no health-related quality of life or patient-reported outcome was reported.

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021); [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.9-2"></a>

###### Limitations stated by the investigators

> “This trial has certain limitations. The 4-week treatment period captures short-term effects but does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes, including hyperkalemia and renal and cardiovascular events. As an exploratory study, these findings will require confirmation in a larger, longer-duration, parallel-arm trial.”
> “Importantly, the short 4-week treatment duration and the exclusion of participants with baseline serum potassium >5.0 mmol/l should be considered when interpreting these data, as both may limit generalizability and could underestimate hyperkalemia risk in routine clinical practice.”
> “The results of the second treatment period can be influenced by carryover from the first treatment period; to address this, we used a 4-week washout period between the treatments.”
> “In longer-term studies of RAAS inhibition, similar hemodynamic effects have been associated with renal protection; however, the present study was not designed to assess long-term renoprotective outcomes.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.9-3"></a>

###### Limitations and caveats in the posted results

> “Limitations of this study include the small sample size and short treatment duration. The 4-week primary endpoint captures short-term pharmacodynamic effects but not the durability of long-term BP lowering or renal outcomes. Second, while urinary protein reduction is a validated surrogate marker for renal risk, confirmation with eGFR slope over longer time periods will be essential.”

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.9-4"></a>

###### Sponsor role and author disclosures

> “SB, MN, and DR are employees of Mineralys Therapeutics.”
> “The trial was designed by Mineralys Therapeutics, with contribution from external scientific advisers.”
> “Medical writing and editorial support was provided by John Watson, PhD, Jonathan Mitchell, PharmD, and Courtney Breuel, ELS, of the Sensified division of Woven Health Collective, LLC (New York, NY), and was funded by Mineralys Therapeutics.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="heading-3.1.6"></a>

#### 3.1.6 Explore-OSA

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.”
> “A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of Lorundrostat in Participants With Moderate to Severe Obstructive Sleep Apnea and Hypertension”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.1-2"></a>

###### Objective stated in the congress abstract

> “To investigate the efficacy and safety of lorundrostat in adults with moderate-to-severe OSA and uHTN.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.1-3"></a>

###### Hypothesis stated by the sponsor at trial initiation

> “The key objective of this trial is to validate the hypothesis that lorundrostat both alleviates the severity of upper airway obstruction and reduces nocturnal hypertension.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.1-4"></a>

###### Proof-of-concept purpose stated by the sponsor

> “This proof-of-concept trial was designed to evaluate the efficacy, safety, and tolerability of lorundrostat in overweight or obese adults with moderate-to-severe OSA and hypertension.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual)”
> “2025-02-28”
> “Primary Completion (Actual)”
> “2025-12-17”
> “Study Completion (Actual)”
> “2025-12-29”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.2-2"></a>

###### Registered locations

> “This study has 27 locations”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.2-3"></a>

###### Planned number of sites at trial initiation

> “Subjects will be at least 18 years old, with a BMI ≥27 kg/m2, and the trial will be conducted across approximately 40 sites.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.2-4"></a>

###### Other study identifiers

> “MLS-101-207”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.2-5"></a>

###### Results reporting status in the ClinicalTrials.gov record

> “Certification/Extension First Submitted”
> “2026-08-17”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Randomized, double-blind, placebo-controlled crossover design in the congress abstract

> “The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover trial in 47 participants with body mass index (BMI) ≥27 kg/m2, apnea-hypopnea index (AHI) ≥15 events/hour, and SBP ≥130 to <180/diastolic BP ≥60 to ≤110 mmHg.”
> “Participants were randomized to one of two treatment sequences: active treatment with lorundrostat 50 mg daily for 4 weeks/2-week washout/placebo for 4 weeks or placebo for 4 weeks/washout/active treatment for 4 weeks.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.3-2"></a>

###### Study periods in the ClinicalTrials.gov record

> “The study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.3-3"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “48” |

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.3-4"></a>

###### Exploratory two-period, two-sequence design described by the sponsor

> “The Explore-OSA trial was a Phase 2, randomized, double-blind, placebo-controlled, two-period, two-sequence (2x2) crossover, exploratory trial that evaluated the safety and efficacy of lorundrostat 50 mg QD administered in the evening in 48 participants with hypertension and moderate-to-severe OSA.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-3.1.6.3-5"></a>

###### Blood pressure monitoring during polysomnography

> “Participants in Explore-OSA received 50 mg of oral, once daily (QD) lorundrostat and placebo in sequential treatment periods, with continuous monitoring of BP during overnight polysomnography.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Key eligibility criteria in the congress abstract

> “The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover trial in 47 participants with body mass index (BMI) ≥27 kg/m2, apnea-hypopnea index (AHI) ≥15 events/hour, and SBP ≥130 to <180/diastolic BP ≥60 to ≤110 mmHg.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.4-2"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Body mass index (BMI) ≥ 27 kilograms per meter square (kg/m^2)”
> “Previously diagnosed with moderate-to-severe OSA”
> “AHI ≥15 events per hour (/hr) prior to Randomization”
> “AOBP SBP of ≥130 and less than or equal to (≤) 180 millimeter of mercury (mmHg) and AOBP diastolic blood pressure (DBP) ≥60 and ≤110 mmHg”
> “Participants on CPAP or PAP therapy are eligible provided they are on PAP for ≥4 hours per night (documented) and for at least 3 months prior to the study enrollment (documented)”
> “Participants not currently on PAP therapy, and not anticipated to start PAP for the duration of the study”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.4-3"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Type 2 diabetes mellitus (T2DM) with a glycosylated hemoglobin (HbA1c) greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit or history of diabetic ketoacidosis in the 6 months prior to the Screening Visit”
> “Participants on a glucagon-like peptide-1 (GLP-1) agonist.”
> “Have diagnosis of central or mixed sleep apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration”
> “Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia”
> “Use of bilevel positive airway pressure (BiPAP) therapy.”
> “eGFR less than (<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) at Screening using serum creatinine or cystatin-C”
> “Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1 month of the Screening Visit”
> “Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6 months prior to Screening”
> “Previously diagnosed, recurrent orthostatic hypotension”
> “Current night-shift worker or anticipated to become a night-shift worker for 3 days continuously during the duration of the study.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.4-4"></a>

###### Ages eligible in the ClinicalTrials.gov record

> “18 Years to 75 Years”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Lorundrostat 50 mg or placebo once daily in the evening

> “After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the apnea-hypopnea index (AHI), the primary endpoint.”
> “Participants in Explore-OSA received 50 mg of oral, once daily (QD) lorundrostat and placebo in sequential treatment periods, with continuous monitoring of BP during overnight polysomnography.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.5-2"></a>

###### Treatment sequences in the congress abstract

> “Participants were randomized to one of two treatment sequences: active treatment with lorundrostat 50 mg daily for 4 weeks/2-week washout/placebo for 4 weeks or placebo for 4 weeks/washout/active treatment for 4 weeks.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.5-3"></a>

###### Interventions and positive airway pressure use in the ClinicalTrials.gov record

> “Lorundrostat tablet.”
> “Lorundrostat matching placebo tablet.”
> “Participants on PAP therapy should comply with PAP therapy for the duration of the study.”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Apnea-Hypopnea Index as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

###### Primary endpoint

> “The primary endpoint was the difference in change in AHI during placebo and active treatment.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-2"></a>

###### Registered primary outcome measure

> “Placebo-adjusted Change From Baseline in AHI at Week 4”
> “Baseline, Week 4”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.6.1-3"></a>

###### Primary endpoint definition stated by the sponsor

> “The primary efficacy endpoint of the trial was absolute change from baseline in apnea-hypopnea index (AHI) after four weeks of active treatment compared to placebo.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.6.1-4"></a>

###### Sponsor rationale for an effect on upper airway obstruction

> “The primary outcome measure is absolute change in the frequency of apnea-hypopnea episodes.”
> “In addition, lorundrostat is anticipated to reduce the severity of upper airway obstruction and associated OSA symptoms such as daytime sleepiness and cognitive impairment.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.6.1-5"></a>

###### Investigator rationale for aldosterone synthase inhibition in obstructive sleep apnea

> “Obesity and OSA promote aldosterone excess, contributing to resistant hypertension and upper airway edema, yet mineralocorticoid receptor antagonists (MRAs) are infrequently prescribed in patients with OSA.”
> “Lorundrostat, a highly selective aldosterone synthase inhibitor (ASI), may restore aldosterone homeostasis and lower blood pressure while also ameliorating OSA.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-6"></a>

###### Apnea-hypopnea index as the most studied measure of sleep apnea severity

> “OSA has well established cardiovascular and neurocognitive sequelae, although the optimal metric to assess its severity and/or potential response to therapy remains unclear.”
> “The apnea-hypopnea index (AHI) is well established; thus, we review its history and predictive value in various different clinical contexts.”
> “Although the AHI is often criticized for its limitations, it remains the best studied metric of OSA severity, albeit imperfect.”

Source: [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)

<a id="topic-3.1.6.6.1-7"></a>

###### Severity thresholds based on the apnea-hypopnea index

> “Moderate OSA is defined as having between 15 and 30 breathing pauses (apnea or hypopnea events) per hour of sleep, while severe OSA indicates more than 30 breathing pauses per hour.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.6.1-8"></a>

###### Apnea-hypopnea index as the primary endpoint of the trials supporting an approved obstructive sleep apnea indication

> “to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.”
> “Moderate OSA was defined as an AHI ≥15 – 30 events/hour on polysomnogram at baseline.”
> “Severe OSA was defined as an AHI ≥30 events/hour on polysomnogram at baseline.”
> “The primary endpoint for Studies 5 and 6 was the change from baseline in the apnea-hypopnea index (AHI) at Week 52.”

Source: [Eli Lilly ZEPBOUND prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf)

<a id="topic-3.1.6.6.1-9"></a>

###### Apnea-hypopnea index as a phase 3 primary endpoint

> “The primary end point was the change in the apnea–hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline.”
> “The AHI was measured by laboratory polysomnography at screening, week 20, and week 52.”

Source: [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)

<a id="topic-3.1.6.6.1-10"></a>

###### Key secondary endpoint: office systolic blood pressure

> “The key secondary endpoint was difference in change in morning office SBP. Additional endpoints included the Functional Outcomes of Sleep Questionnaire (FOSQ)-10.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-11"></a>

###### Secondary endpoints stated by the sponsor

> “The first secondary endpoint was AOBP, and additional endpoints were nighttime BP and sleep and cardiovascular health measures.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.6.1-12"></a>

###### Key secondary objective stated at trial initiation

> “The key secondary objective is to quantify blood pressure throughout the night using continuous BP monitoring during performance of a standard sleep study without the benefit of CPAP. Standard patient reported outcomes, specific to OSA will also be assessed.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.6.1-13"></a>

###### Registered secondary outcome measures

> “Placebo-adjusted Change From Baseline in Nighttime Average Systolic Blood Pressure (SBP) at Week 4”
> “Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) SBP at Week 4”
> “Placebo-adjusted Change From Baseline in Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10) at Week 4”
> “Placebo-adjusted Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 4”
> “Placebo-adjusted Change From Baseline in Patient-Reported Outcomes Measurement Information System - Sleep Disturbance (PROMIS-SD) at Week 4”
> “Placebo-adjusted Change From Baseline in PROMIS Sleep-Related Impairment (SRI) at Week 4”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.6.1-14"></a>

###### Rationale for blood pressure endpoints in obstructive sleep apnea

> “Uncontrolled hypertension (uHTN), a major driver of adverse cardiovascular (CV) outcomes, affects up to 80% of patients with obstructive sleep apnea (OSA).”
> “While established OSA therapies such as positive airway pressure (PAP), hypoglossal nerve stimulation, and mandibular advancement devices can effectively restore upper airway patency, their effect on systolic blood pressure (SBP) reduction is generally modest (<5 mmHg).”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.6.1-15"></a>

###### Systolic blood pressure reduction and major cardiovascular events

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Planned enrollment at trial initiation

> “The planned Phase 2 clinical trial is a placebo-controlled, crossover study to evaluate the safety and efficacy of lorundrostat 50mg taken once daily in the evening in approximately 40 subjects with moderate-to-severe OSA.”

Source: [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)

<a id="topic-3.1.6.7.1-2"></a>

###### Enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual)”
> “48”

Source: [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)

<a id="topic-3.1.6.7.1-3"></a>

###### Participants reported in the topline release

> “The Explore-OSA trial was a Phase 2 exploratory trial of lorundrostat in forty-eight participants with an average body mass index (BMI) of 38.2 kg/m2, an average apnea-hypopnea index (AHI) of 48.5 events/hr and an average systolic blood pressure (BP) of 142.3 mmHg (range 131-175 mmHg).”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.7.1-4"></a>

###### Participants reported in the congress abstract

> “The Explore-OSA trial (NCT06785454) was a randomized, double-blind, placebo-controlled, crossover trial in 47 participants with body mass index (BMI) ≥27 kg/m2, apnea-hypopnea index (AHI) ≥15 events/hour, and SBP ≥130 to <180/diastolic BP ≥60 to ≤110 mmHg.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

###### Parallel-arm and crossover analyses

> “In a preplanned parallel arm analysis of the first treatment period providing a point estimate of efficacy, the placebo-adjusted reduction in SBP with lorundrostat was 10.1 mmHg (P=0.0089).”
> “In the crossover analysis of both treatment periods, the placebo-adjusted reduction in SBP was 6.2 mmHg (P<0.0003).”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.7.2-2"></a>

###### Topline status of the March 2026 analysis

> “Analysis is ongoing for other endpoints in the trial and will be reported in future publications or medical meetings.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Body mass index, apnea-hypopnea index, and systolic blood pressure at baseline

> “The Explore-OSA trial was a Phase 2 exploratory trial of lorundrostat in forty-eight participants with an average body mass index (BMI) of 38.2 kg/m2, an average apnea-hypopnea index (AHI) of 48.5 events/hr and an average systolic blood pressure (BP) of 142.3 mmHg (range 131-175 mmHg).”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.2-2"></a>

###### Positive airway pressure use

> “The Explore-OSA trial, in which more than a third of participants were using PAP therapy, did not demonstrate a difference in AHI response between lorundrostat- and placebo-treated participants.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Summary: systolic blood pressure figures in the congress abstract and the company releases

The congress abstract reports the preplanned parallel-arm analysis of the first treatment period as a placebo-adjusted reduction in systolic blood pressure of 10.1 mmHg (P=0.0089). The NDA acceptance release and the AHA Hypertension 2026 release report within-group reductions of 11.1 mmHg with lorundrostat (p<0.0001) and 1.0 mmHg with placebo (p=NS) at week 4, and the NDA acceptance release attributes these figures to the pre-planned parallel arm analysis of the first period; the difference between the two within-group figures is 10.1 mmHg. The abstract and the NDA acceptance release both report a placebo-adjusted reduction of 6.2 mmHg (P<0.0003) in the crossover analysis of both treatment periods. The NDA acceptance release reports topline results.

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08); [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for); [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="topic-3.1.6.8.3-2"></a>

###### Primary endpoint: apnea-hypopnea index not met

> “There was no difference in AHI response between lorundrostat- and placebo-treated participants.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.3-3"></a>

###### Primary endpoint result in the topline release

> “After four weeks of treatment, lorundrostat 50 mg dosed in the evening did not demonstrate a clinically meaningful difference relative to placebo on the apnea-hypopnea index (AHI), the primary endpoint.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.3-4"></a>

###### Office systolic blood pressure: placebo-adjusted estimates in the congress abstract

> “In a preplanned parallel arm analysis of the first treatment period providing a point estimate of efficacy, the placebo-adjusted reduction in SBP with lorundrostat was 10.1 mmHg (P=0.0089).”
> “In the crossover analysis of both treatment periods, the placebo-adjusted reduction in SBP was 6.2 mmHg (P<0.0003).”
> “A clinically meaningful reduction in office SBP in adults with moderate-to-severe OSA and hypertension was seen, with similar magnitude compared with prior pivotal lorundrostat treatment trials in patients with uHTN.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.3-5"></a>

###### Office systolic blood pressure: within-group changes and crossover estimate in the topline release

> “At week four, the trial demonstrated an 11.1 mmHg (p < 0.0001) and a 1.0 mmHg (p = NS) BP reduction with lorundrostat and placebo, respectively, in the pre-planned parallel arm analysis of the first period. There was a 6.2 mmHg placebo-adjusted reduction (p < 0.0003) in BP in the crossover analysis.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.3-6"></a>

###### Final results reported by the sponsor

> “Participants receiving lorundrostat 50 mg once daily in the evening achieved clinically meaningful reductions in morning SBP of 11.1 mmHg at Week 4 (p<0.0001), compared with 1.0 mmHg reduction for participants receiving placebo (p=NS), although no measurable change in apnea-hypopnea indices were observed with lorundrostat.”

Source: [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="topic-3.1.6.8.3-7"></a>

###### Nighttime blood pressure

No evidence found.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

###### Functional Outcomes of Sleep Questionnaire-10

> “Changes in FOSQ-10 were not observed.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.4-2"></a>

###### Epworth Sleepiness Scale and PROMIS sleep measures

No evidence found.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Serious adverse events and tolerability in the congress abstract

> “There were no serious adverse events reported (Table 2).”
> “Lorundrostat was well tolerated.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.8.5-2"></a>

###### Serum potassium in the topline release

> “Lorundrostat demonstrated a favorable safety profile and was well tolerated, with no serum potassium excursions above 5.5 mmol/L.”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.8.5-3"></a>

###### Safety in the final results release

> “In the study, lorundrostat exhibited a favorable safety and tolerability profile, and there was no evidence of significant safety events, including hyperkalemia (high serum potassium).”

Source: [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

Explore-OSA was a phase 2 crossover trial with two 4-week treatment periods separated by a 2-week washout; the registry lists 48 enrolled participants and the congress abstract describes 47. The primary endpoint, the placebo-adjusted change in apnea-hypopnea index at week 4, showed “no difference in AHI response between lorundrostat- and placebo-treated participants”. Office systolic blood pressure was a secondary endpoint, and the public results come from a congress abstract and company releases; no peer-reviewed publication or posted registry results were located, and the registry record shows a certification/extension submission dated 2026-08-17. The registry lists nighttime average systolic blood pressure as the first secondary outcome measure and also lists the Epworth Sleepiness Scale and two PROMIS sleep measures; no result for any of these was located in the public documents. The parallel-arm systolic blood pressure estimate uses the first treatment period alone, and the abstract and the company releases state it differently. The abstract states that “more than a third of participants were using PAP therapy”. Public safety reporting is limited to the absence of serious adverse events and of serum potassium values above 5.5 mmol/L. Eligibility excluded participants with eGFR below 45 mL/min/1.73 m2 and participants taking a GLP-1 agonist, and the registry lists 27 locations.

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08); [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454); [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="topic-3.1.6.9-2"></a>

###### Conclusions stated by the investigators

> “The Explore-OSA trial, in which more than a third of participants were using PAP therapy, did not demonstrate a difference in AHI response between lorundrostat- and placebo-treated participants.”
> “Given the high prevalence of aldosterone dysregulation and its association with cardiometabolic disease in OSA, a longer-term CV outcomes trial of lorundrostat should be considered.”

Source: [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)

<a id="topic-3.1.6.9-3"></a>

###### Topline status of the March 2026 results

> “topline results that we report are based on a preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial”

Source: [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)

<a id="heading-3.1.7"></a>

#### 3.1.7 MT-4129-E01

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses

> “This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of lorundrostat in healthy adult participants.”
> “This first‐in‐human dose escalation study evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple oral doses of lorundrostat, a highly selective CYP11B2 inhibitor. In addition, this study also compared lorundrostat PK in females and males and older adult (≥65 years old) and younger adult participants.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.1-2"></a>

###### Registered purpose and official title

> “The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of MT-4129 in healthy subjects.”
> “A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.1-3"></a>

###### Concentration-QTc evaluation within the first-in-human study

> “The effect of lorundrostat on the QTc interval was assessed as part of a first-in-human study with 64 participants who received a single dose of lorundrostat 5-800 mg or placebo (single ascending dose [SAD]) and 36 participants who received multiple doses of lorundrostat 40-360 mg/day or placebo for 7 days (multiple ascending dose [MAD])”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Single center in the Netherlands, November 2016 to May 2017

> “A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017)”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.2-2"></a>

###### Registered site, sponsor, and dates

| Field | Quoted record |
| --- | --- |
| Location | “Pharmaceutical Research Associates (PRA) Health Sciences” |
| Sponsor | “Tanabe Pharma Corporation” |
| Other study ID number | “MT-4129-E01” |
| Study start | “2016-11” |
| Primary completion (actual) | “2017-05” |
| Study completion (actual) | “2017-05” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.2-3"></a>

###### Ethics approval and contract research organization

> “The study was approved by the local independent ethics committee; the BEBO foundation in Assen, Netherlands; and the Central Committee on Research Involving Human Subjects in The Hague, Netherlands; and conducted according to the provisions of the Declaration of Helsinki.”
> “Thijs van Iersel and Jan Jaap van Lier are employees of ICON, the CRO which conducted the clinical study.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Four-part, randomized, double-blind, placebo-controlled design

> “A four‐part, randomized, double‐blind, placebo‐controlled, first‐in‐human study was performed (single‐center in the Netherlands; November 16, 2016–May 01, 2017) to determine the safety, tolerability, PK, and PD of single ascending doses (SADs; part 1) and multiple ascending doses (MADs; part 2) of lorundrostat free base in a capsule in healthy participants (EudraCT Number: 2016–003500‐32).”
> “The study also assessed sex‐ (part 3) and age‐related (part 4) effects on the PK of a single dose of lorundrostat.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.3-2"></a>

###### Exploratory food comparison

> “An exploratory comparison of the effect of food on PK profiles of lorundrostat was also performed by assessing single‐dose PK profiles of lorundrostat in the fasted state (part 1) vs. PK profiles of lorundrostat in the fed state (part 2 after the first‐dose administered).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.3-3"></a>

###### Sentinel dosing and dose escalation rules

> “All cohorts included two sentinel participants of whom one received lorundrostat and one received matching placebo. The remaining six participants, of whom five received lorundrostat and one received placebo, were dosed ≥24 h later.”
> “Doses were administered in an ascending order per cohort. After each cohort, all safety data were reviewed prior to initiating the next dose cohort.”
> “Progression to the next dose level was based on available data from part 1 and the preceding dose cohort in part 2.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.3-4"></a>

###### Registered design details

| Field | Quoted record |
| --- | --- |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Other” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.3-5"></a>

###### Holter electrocardiograms matched to pharmacokinetic sampling

> “Serial ECGs were extracted from continuous recordings (Holter) at prespecified time points and were matched with blood collections for pharmacokinetic analysis through 24 hours postdose on Day 1 in the SAD study and on Days 1 and 7 in the MAD study”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Healthy Caucasian men, women, and older men

> “Healthy male Caucasian participants (parts 1 and 2) aged 18–55 years (inclusive), healthy non‐pregnant and non‐lactating female Caucasian participants (part 3) aged 18–55 years (inclusive), and healthy male Caucasian participants aged ≥65 years (part 4) were eligible.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.4-2"></a>

###### Registered inclusion and exclusion criteria

> “Healthy and free from clinically significant illness or disease”
> “Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65”
> “A body weight of ≥60 kg for males and ≥50 kg for females, and a body mass index ranging from 18 to 30 kg/m2”
> “Clinically significant endocrine, thyroid, hepatic, respiratory, gastro intestinal, neurological, renal, cardiovascular disease, or history of any significant psychiatric/psychotic illness disorder”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Part 1: single ascending doses of 5 to 800 mg, fasted

> “In part 1, in each dose cohort, six participants were randomized to receive a single dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state.”
> “The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg (5‐mg starting dose rationale provided in Table S1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.5-2"></a>

###### Part 2: once-daily doses of 40, 120, or 360 mg for 7 days, fed

> “In part 2, in each cohort, nine participants received daily doses of lorundrostat and three participants received matching placebo in the fed state from Day 1 to Day 7.”
> “The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg. An adrenocorticotropic hormone (ACTH) challenge test was performed on Day ‐2 and Day 6 to evaluate the lorundrostat selectivity for aldosterone synthesis.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.5-3"></a>

###### Parts 3 and 4: single 100 mg dose in women and in men aged 65 years or older

> “In one cohort of eight females (part 3) and one cohort of eight males aged ≥65 years (part 4), six participants were randomized to receive a single 100‐mg dose of lorundrostat and two participants were randomized to receive matching placebo in the fasted state in each part. The results were compared with those at the same dose in part 1.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.5-4"></a>

###### Capsule formulation relative to the phase 2 tablet

> “The lorundrostat capsule formulation used in the first‐in‐human studies reported here is equivalent to ~50% of exposure seen in the tablet formulation used in the phase II study (doses used in the phase II study included 12.5 mg once daily and twice daily, 25 mg twice daily, 50 mg once daily, and 100 mg once daily).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Adverse Events as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

###### Registered primary outcome measures

| Primary outcome measure | Time frame |
| --- | --- |
| “Safety and Tolerability as measured by incidence and severity of adverse events” | “Up to Day 14” |
| “Safety and Tolerability as measured by vital signs” | “Up to Day 14” |
| “Safety and Tolerability as measured by ECG” | “Up to Day 14” |
| “Safety and Tolerability as measured by clinical laboratory assessments” | “Up to Day 14” |
| “Safety and Tolerability as measured by Hormone assessments” | “Up to Day 10” |
| “Safety and Tolerability as measured by physical examination” | “Up to Day 14” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.6.1-2"></a>

###### Safety assessments in the publication

> “Safety assessments included treatment‐emergent adverse events (TEAEs), treatment‐related TEAEs, vital signs, 12‐lead electrocardiograms (ECGs), clinical laboratory evaluations, and physical examinations.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.6.1-3"></a>

###### Purpose of phase 1 studies in federal regulation

> “Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.”
> “During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies.”

Source: [Electronic Code of Federal Regulations, 21 CFR 312.21 (2026)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.21)

<a id="topic-3.1.7.6.1-4"></a>

###### Rationale for cortisol and ACTH-stimulation safety assessments

> “CYP11B1, a key enzyme in glucocorticoid biosynthesis, has a high homology to CYP11B2 (>93%). High selectivity for CYP11B2 over CYP11B1 is an essential characteristic for a successful aldosterone synthase inhibitor.”
> “Osilodrostat, the first aldosterone synthase inhibitor, lacked high selectivity, resulted in blunted adrenocorticotropic hormone‐stimulated cortisol release in some patients, and instead became a treatment for Cushing's disease.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.6.1-5"></a>

###### Rationale for the concentration-QTc analysis

> “Regulatory guidance recommends that the effects of new drug candidates on ventricular depolarization and subsequent repolarization (QT interval) be rigorously investigated”
> “regulatory guidance documents allow for a waiver of a thorough QT study in the case that a >10 ms effect on the heart-rate corrected QT (QTc) interval at clinically relevant drug concentrations can be excluded”
> “The primary analysis was an assessment of the relationship of the plasma concentration of lorundrostat and change from baseline in QTc, corrected for HR using Fridericia’s method (ΔQTcF)”
> “The secondary analysis was a by-timepoint analysis of ΔQTcF for lorundrostat versus placebo”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.6.1-6"></a>

###### Registered secondary pharmacokinetic and pharmacodynamic outcome measures

> “Maximum observed plasma concentration (Cmax) of MT-4129”
> “Apparent terminal elimination half-life (t1/2) of MT-4129”
> “Renal clearance (CLR) of MT-4129”
> “Plasma aldosterone”
> “Serum cortisol”
> “Urinary sodium”

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Participants screened and randomized

> “A total of 245 participants were screened, of which 116 were randomized.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

| Field | Quoted record |
| --- | --- |
| Enrollment (estimated) | “116” |

Source: [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)

<a id="topic-3.1.7.7.1-2"></a>

###### Participants per part

> “Part 1 (SAD) included 64 male participants between 18 and 55 years old. Part 2 (MAD) included 36 male participants between 19 and 54 years of age. Part 3 (sex effect) included eight female participants between 20 and 35 years of age. Part 4 (age effect) included eight male participants between 68 and 80 years of age.”
> “The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.7.1-3"></a>

###### Participants in the concentration-QTc analysis groups

> “The SAD and MAD QT/QTcF analysis groups included 60 (46 lorundrostat, 14 placebo) and 32 (23 lorundrostat, 9 placebo) healthy participants, respectively”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

###### Safety, pharmacokinetic, and pharmacodynamic analysis sets

> “Safety analyses used the safety analysis set (all participants who received at least one dose of study drug).”
> “All PK analyses used the PK analysis set (all participants who received at least one dose of study drug other than placebo and had PK data considered sufficient and interpretable).”
> “All PD analyses used the PD analysis set (all participants who received at least one dose of study drug, had at least one post‐dose PD assessment, and PD data considered sufficient and interpretable).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.7.2-2"></a>

###### Dose proportionality, sex, age, and food comparisons

> “Dose proportionality was concluded if the 95% confidence interval (CI) for slope (β) included the value 1.”
> “Difference in least square means and corresponding 90% CI were back‐transformed to obtain the estimates of geometric mean ratios and their CI for females vs. males and participants ≥ 65 years old vs. 18–55 years old. The result was judged to be statistically significant if the 90% CI did not include 1.”
> “No formal statistical comparison was performed for an exploratory comparison of PK between fasted (part 1) and fed (part 2, after the first‐dose administered) states.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.7.2-3"></a>

###### Pharmacokinetic and QTc analysis set

> “The relationship of lorundrostat plasma concentration and the ΔΔQTcF was assessed in the PK/QTc analysis set (defined as all participants with ≥1 set of PK and ΔQTcF data from the same time point) using linear mixed-effects modeling with ΔQTcF as the dependent variable, lorundrostat concentration as the explanatory variable, and treatment and time as fixed effects.”
> “All cardiodynamic analyses were performed separately for the SAD and MAD studies”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

###### Completion by part

> “All participants randomized in parts 1, 3, and 4 completed the study as per protocol. One participant in part 2 did not complete the study.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.1-2"></a>

###### Withdrawal for sinus tachycardia in the 360 mg cohort

> “One participant in cohort 3 of part 2 was withdrawn on Day 2 because of an AE of sinus tachycardia (117 bpm) before dosing on Day 2, and he received only one dose of 360 mg lorundrostat on Day 1 (Table 2).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

###### Race and ethnicity of participants

> “All participants were white and none were of Hispanic or Latino ethnicity.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.2-2"></a>

###### Demographics by dose group and part

| Dose group | Age, years, mean (SD) | Sex, n (%) | Weight, kg, mean (SD) | BMI (kg/m2), mean (SD) |
| --- | --- | --- | --- | --- |
| Part 1, placebo (n = 16) | “31.2 (12.9)” | Male: “16 (100)” | “81.0 (7.8)” | “24.8 (2.1)” |
| Part 1, 5 mg (n = 6) | “29.0 (12.3)” | Male: “6 (100)” | “71.5 (5.3)” | “22.5 (1.8)” |
| Part 1, 10 mg (n = 6) | “31.7 (13.1)” | Male: “6 (100)” | “78.3 (12.4)” | “23.9 (3.7)” |
| Part 1, 20 mg (n = 6) | “27.5 (12.7)” | Male: “6 (100)” | “76.2 (7.6)” | “23.8 (2.8)” |
| Part 1, 50 mg (n = 6) | “28.2 (13.8)” | Male: “6 (100)” | “77.3 (7.2)” | “22.8 (2.2)” |
| Part 1, 100 mg (n = 6) | “27.8 (11.9)” | Male: “6 (100)” | “79.2 (8.7)” | “23.4 (1.9)” |
| Part 1, 200 mg (n = 6) | “28.3 (11.8)” | Male: “6 (100)” | “81.4 (12.3)” | “23.4 (2.3)” |
| Part 1, 400 mg (n = 6) | “28.5 (11.9)” | Male: “6 (100)” | “84.2 (6.8)” | “24.2 (2.8)” |
| Part 1, 800 mg (n = 6) | “33.2 (15.8)” | Male: “6 (100)” | “85.1 (9.9)” | “25.1 (2.9)” |
| Part 2, placebo (n = 9) | “29.3 (11.9)” | Male: “9 (100)” | “78.5 (10.2)” | “23.6 (2.9)” |
| Part 2, 40 mg (n = 9) | “29.2 (10.4)” | Male: “9 (100)” | “76.7 (8.6)” | “23.0 (2.3)” |
| Part 2, 120 mg (n = 9) | “26.3 (5.6)” | Male: “9 (100)” | “77.8 (12.2)” | “22.8 (2.6)” |
| Part 2, 360 mg (n = 9) | “30.8 (11.6)” | Male: “9 (100)” | “76.4 (11.7)” | “23.1 (4.1)” |
| Part 3, placebo (n = 2) | “23.0 (4.2)” | Female: “2 (100)” | “59.9 (8.9)” | “22.3 (3.3)” |
| Part 3, 100 mg (n = 6) | “25.5 (5.8)” | Female: “6 (100)” | “60.8 (4.7)” | “22.2 (1.7)” |
| Part 4, placebo (n = 2) | “72.5 (3.5)” | Male: “2 (100)” | “77.2 (10.6)” | “27.9 (1.0)” |
| Part 4, 100 mg (n = 6) | “72.2 (4.1)” | Male: “6 (100)” | “77.9 (6.3)” | “25.1 (1.9)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.2-3"></a>

###### Baseline electrocardiogram parameters

> “For both groups, mean baseline ECG parameters were consistent with those from healthy populations, with mean QTcF between 388.7 and 401.0 ms (SAD) and 394.8 and 402.1 ms (MAD)”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### In vitro selectivity for CYP11B2 over CYP11B1

> “Lorundrostat inhibited hCYP11B2 and hCYP11B1 with inhibition constant values of 1.27 nmol/L and 475 nmol/L, respectively. These results indicate that lorundrostat inhibits CYP11B2 with 374‐fold selectivity over CYP11B1 (Figure 1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-2"></a>

###### Single-dose pharmacokinetics

> “Following single oral doses across 5–800 mg, plasma drug concentration–time profiles demonstrated rapid absorption with a median time to maximum concentration (T max) 1.0–1.5 h (Table 3; Figure 1b); the mean terminal half‐life (t 1/2) ranged from 7.9 to 10.5 h, and apparent clearance was comparable, ranging from 18.7 to 27.6 L/h.”
> “In contrast, the estimate of the slope (95% CI) for C max versus dose was 1.104 (1.043–1.164), and a slightly greater than dose proportional increase in C max was observed over the range 5–800 mg (Figure S1).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-3"></a>

###### Multiple-dose pharmacokinetics and accumulation

> “A steady state was achieved by approximately Day 5 and very slight accumulation of lorundrostat was observed following multiple dosing compared with Day 1, with the mean rate of accumulation values for AUC0–24 ranging from 1.15 to 1.19 across the entire dose range. Consistent with single‐dose administration, the mean t 1/2 values on Day 7 ranged from 9.1 to 11.9 h.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-4"></a>

###### Plasma pharmacokinetic parameters by dose

| Dose group | AUC, ng × h/mL, mean (SD) | Cmax, ng/mL, mean (SD) | t1/2, h, mean (SD) | Tmax, h, median (minimum–maximum) |
| --- | --- | --- | --- | --- |
| Single dose, 5 mg (AUC0–∞) | “232 (25)” | “36.7 (6.7)” | “8.3 (0.7)” | “1.5 (1.0–3.0)” |
| Single dose, 10 mg (AUC0–∞) | “452 (46)” | “76.3 (20.4)” | “7.9 (0.9)” | “1.3 (1.0–1.5)” |
| Single dose, 20 mg (AUC0–∞) | “770 (183)” | “140.6 (76.1)” | “10.0 (1.9)” | “1.5 (1.0–3.0)” |
| Single dose, 50 mg (AUC0–∞) | “2157 (259)” | “572.8 (205.7)” | “9.1 (1.9)” | “1.0 (0.5–3.0)” |
| Single dose, 100 mg (AUC0–∞) | “5376 (495)” | “1211.0 (248.3)” | “10.0 (0.9)” | “1.5 (0.5–3.0)” |
| Single dose, 200 mg (AUC0–∞) | “10,660 (3483)” | “2847.5 (1015.2)” | “9.9 (3.6)” | “1.3 (1.0–3.0)” |
| Single dose, 400 mg (AUC0–∞) | “17,275 (2906)” | “4454.8 (862.4)” | “9.7 (2.3)” | “1.3 (0.5–3.0)” |
| Single dose, 800 mg (AUC0–∞) | “29,385 (3623)” | “7708.5 (1617.1)” | “10.5 (2.1)” | “1.5 (0.5–4.0)” |
| Multiple dose, 40 mg, Day 7 (AUC0–24) | “1795.0 (312.0)” | “365.1 (46.5)” | “9.1 (1.8)” | “2.0 (1.0–3.0)” |
| Multiple dose, 120 mg, Day 7 (AUC0–24) | “5816.0 (1315.0)” | “1038.7 (342.8)” | “11.9 (2.5)” | “1.5 (0.5–5.0)” |
| Multiple dose, 360 mg, Day 7 (AUC0–24) | “21825.0 (3955.0)” | “3812.1 (1282.3)” | “9.2 (2.5)” | “2.5 (1.0–4.0)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-5"></a>

###### Urinary excretion of unchanged drug and renal clearance

> “After a single dose of 40–360 mg of lorundrostat on Day 1, the fraction of the dose excreted in the urine as unchanged was low, with mean values ranging between 1.2%–1.8%.”
> “After 7 days of once‐daily doses of lorundrostat, the fraction of the dose excreted in the urine as unchanged drug was low for all multiple‐dose levels, with mean values ranging between 2.3% and 2.6%. The fraction of the lorundrostat dose excreted remained consistent over the multiple‐dose range tested. Renal clearance was low and generally similar across all multiple‐dose levels (mean CLR ranging between 0.4 and 0.6 L/h on Day 7).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-6"></a>

###### Effects of sex, age, and food on pharmacokinetics

> “In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4).”
> “In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4).”
> “Based on the dose escalation data of the first cohort in part 2 where lorundrostat was administered in the fed state, the PK profile did not appear to be affected compared with part 1 where lorundrostat was administered in the fasted state.”
> “Separate from the study we report in this article, a formal food effect study has been conducted and confirms lack of effect of food on the absorption and PK of lorundrostat (tablet formulation; data on file).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-7"></a>

###### Plasma aldosterone suppression after single doses

> “At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose. PAC showed maximum decreases at 4 h and 8 h post‐dose of ~80% compared with placebo. Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-8"></a>

###### Aldosterone after multiple doses and rebound after the last dose

> “Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d). From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-9"></a>

###### ACTH-stimulated aldosterone and cortisol

> “During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-10"></a>

###### Renin activity, 11-deoxycorticosterone, and urinary sodium

> “Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b).”
> “Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d). In the MAD, the urine sodium and urinary log10 (10 × Na+/K+) ratio was initially increased on Day 1 at all dose levels, but the ratio returned to baseline levels at the next sampling timepoint at the end of the dosing period on Day 7.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.3-11"></a>

###### Implications for dose selection

> “Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Serious and overall treatment-emergent adverse events

> “Lorundrostat was well tolerated and no serious TEAEs occurred during the study.”
> “The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]). Across all cohorts, dizziness (of mild intensity) was reported by nine (10.3%) lorundrostat‐treated participants compared with one (3.4%) placebo‐treated participant.”
> “There were no clinically significant findings with respect to clinical laboratory, vital signs, ECGs, or physical examination.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-2"></a>

###### Treatment-related adverse events after single doses

| Preferred term, n (%) | Placebo (n = 16) | 5 mg (n = 6) | 10 mg (n = 6) | 20 mg (n = 6) | 50 mg (n = 6) | 100 mg (n = 6) | 200 mg (n = 6) | 400 mg (n = 6) | 800 mg (n = 6) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Headache | “2 (12.5)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” |
| Somnolence | “1 (6.3)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Dizziness | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” |
| Diarrhea | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “1 (16.7)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Nausea | “1 (6.3)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Asthenia | “1 (6.3)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-3"></a>

###### Treatment-related adverse events after multiple doses

| Preferred term, n (%) | Part 2, placebo (n = 9) | Part 2, 40 mg (n = 9) | Part 2, 120 mg (n = 9) | Part 2, 360 mg (n = 9) |
| --- | --- | --- | --- | --- |
| Headache | “2 (22.2)” | “1 (11.1)” | “1 (11.1)” | “0 (0.0)” |
| Dizziness postural | “0 (0.0)” | “1 (11.1)” | “1 (11.1)” | “1 (11.1)” |
| Somnolence | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (11.1)” |
| Dizziness | “0 (0.0)” | “0 (0.0)” | “1 (11.1)” | “0 (0.0)” |
| Dysgeusia | “0 (0.0)” | “1 (11.1)” | “0 (0.0)” | “0 (0.0)” |
| Sinus tachycardia | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” | “1 (11.1)” |
| Dyspnea | “1 (11.1)” | “0 (0.0)” | “0 (0.0)” | “0 (0.0)” |
| Nausea | “0 (0.0)” | “1 (11.1)” | “0 (0.0)” | “0 (0.0)” |

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

> “There were no treatment‐related TEAEs in the Sex Effect Part 3 cohort.”
> “These observations suggest that a stimulus–response reaction to some of the study procedures was more plausible than a relationship to the study drug.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-4"></a>

###### Serum potassium during multiple dosing

> “Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment. There was a maximum mean increase of 0.44 mmol/L after 40 mg on Day 8, 0.6 mmol/L after 120 mg on Day 7, and 0.48 mmol/L after 360 mg on Day 6. None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.”
> “Upon cessation of lorundrostat treatment, serum potassium levels rapidly fell toward pretreatment baseline.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.8.5-5"></a>

###### Concentration-QTc results

> “On the basis of this analysis, an effect on placebo-corrected ΔQTcF (ΔΔQTcF) >10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~7800 ng/mL”
> “On the basis of the MAD results, an effect on ΔΔQTcF exceeding 10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~6175 ng/mL”
> “There were no participants in the SAD and MAD studies with QTcF >450 ms or ΔQTcF >30 ms”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.8.5-6"></a>

###### Exposure margin and waiver of a thorough QT study

> “These results demonstrate the absence of QT interval prolongation by plasma exposure of up to approximately 7800 ng/mL lorundrostat”
> “This concentration is 4.8-fold higher than the predicted maximum observed plasma concentration (Cmax) at the maximum clinically efficacious dosage of 100 mg once daily and is also higher than the high clinical exposure scenario when lorundrostat is given with strong CYP3A4 inhibitors (~1.2-fold increase in Cmax)”
> “On the basis of these data, the regulatory requirement for a thorough QT study was waived”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.8.5-7"></a>

###### Heart rate, PR, and QRS intervals

> “In both the SAD and MAD studies and at all studied doses, lorundrostat did not have clinically relevant effects on the other assessed cardiodynamic and ECG parameters”
> “In the categorical analyses, there was 1 bradycardic outlier at 1 time point in the SAD study”
> “There were no outliers for HR in the MAD study, or for PR or QRS (both studies)”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary

MT-4129-E01 randomized 116 healthy white participants at one center in the Netherlands. Parts 1 and 2 enrolled men aged 18 to 55 years only, and the effects of sex and of age were each assessed in one cohort of 8 participants, 6 of whom received a single 100 mg dose. Multiple dosing lasted 7 days, so the study gives no information on longer treatment or on people with hypertension. Lorundrostat was given as a capsule whose exposure the authors state is about 50% of that of the tablet used in the phase 2 study, the comparison of fed and fasted pharmacokinetics was exploratory with no formal statistical comparison, and the formal tablet food effect study is described as “data on file”. The ClinicalTrials.gov record lists enrollment as estimated. The concentration-QTc analysis is reported in a congress poster by authors from Mineralys Therapeutics and Clario. The publication states that the studies it reports were funded by Mineralys Therapeutics, while the registry record names Tanabe Pharma Corporation as sponsor, and the authors include employees of Mitsubishi Tanabe Pharma Corporation, Mineralys Therapeutics, and ICON, the contract research organization that conducted the study.

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/); [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132); [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-3.1.7.9-2"></a>

###### Healthy male participants in the dose-escalation parts

> “Oral administration of lorundrostat, either as single dose up to 800 mg under fasted conditions (SAD part 1) or as once‐daily dose up to 360 mg for 7 days under fed conditions (MAD part 2), was well tolerated with a favorable safety profile in a group of healthy male participants.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.9-3"></a>

###### Duration of sodium depletion not addressed

> “Although the urinary electrolyte measurements confirmed that there was a brief period of natriuresis at all doses tested, the duration and stability of the sodium depletion is not addressed by that measurement.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.9-4"></a>

###### Funding and author affiliations

> “All studies reported in this manuscript were funded by Mineralys Therapeutics, Inc.”
> “Hidetoshi Shimizu, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, and Kanami Sugimoto‐Kawabata are employees of Mitsubishi Tanabe Pharma Corporation, which invented and out‐licensed the compound to Mineralys Therapeutics, Inc.”
> “Michael A. Tortorici, Stephen Djedjos, and David M. Rodman are employees of Mineralys Therapeutics, Inc.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-3.1.7.9-5"></a>

###### Sponsorship of the concentration-QTc analysis

> “The study was sponsored by Mineralys Therapeutics (Radnor, PA, USA).”
> “MAT and DAR: Employment: Mineralys Therapeutics; BD: Employment: Clario; stock ownership: Clario; HX: Employment: Clario; SS: Consultant: Mineralys Therapeutics.”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
